Compositions, devices, systems, and methods for using a nanopore

ABSTRACT

The invention herein disclosed provides for devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore in the absence of requiring a terminating nucleotide. The devices and methods are also used to determine rapidly (˜&gt;50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of drug discovery, molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a divisional application of and claimspriority to pending U.S. patent application Ser. No. 12/459,059 filed on26 Jun. 2009, which is a continuation-in-part of and claims priority toInternational Patent Application No. PCT/US2008/004467, filed 4 Apr.2008, which, in turn, claimed priority to and benefits of the following:U.S. Provisional Patent Application Ser. No. 60/921,787 entitled“Methods To Limit Enzyme Activity To One Molecule Or Complex Using ANanopore”, filed 4 Apr. 2007; U.S. Provisional Patent Application Ser.No. 60/931,115 entitled “Methods For Sequencing Polynucleotides BySynthesis Using A Nanopore”, filed 21 May 2007; U.S. Provisional PatentApplication Ser. No. 60/962,530 entitled “Methods For Positioning SingleMolecules At A Defined Site” filed 30 Jul. 2007; U.S. Provisional PatentApplication Ser. 60/967,539 entitled “Methods For Manufacture of VeryLarge Scale Arrays of Independently Addressable Nanopores and Methodsfor Their Use” filed 4 Sep. 2007; and U.S. Provisional PatentApplication Ser. No. 61/062,391 entitled “Feedback Control Of A SingleTethered Polynucleotide Suspended In A Nanopore To Repeatedly ProbePolynucleotide-Binding Proteins”, filed 25 Jan. 2008; all of which areherein incorporated by reference in their entirety for all purposes.

STATEMENT OF GOVERNMENTAL SUPPORT

This invention was made partly using funds from the National HumanGenome Research Institute grant numbers HG003703-01 and HG004035-01, andfrom the National Institute of General Medical Sciences grant numberGM073617-01A1. The U.S. Federal Government has certain rights to thisinvention.

REFERENCE TO SEQUENCE LISTING, COMPUTER PROGRAM, OR COMPACT DISK

In accordance with “Legal Framework for EFS-Web,” (6 Apr. 11) Applicantssubmit herewith a sequence listing as an ASCII text file. The text filewill serve as both the paper copy required by 37 CFR 1.821(c) and thecomputer readable form (CRF) required by 37 CFR 1.821(e). The date ofcreation of the file was Feb. 26, 2014, and the size of the ASCII textfile in bytes is 924. Applicants incorporate the contents of thesequence listing by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention herein disclosed provides for devices and methods that canregulate when an individual polymer is acted upon by another compound,for example, a compound, such as a drug composition, a drug candidate, alipid, an oligonucleotide, a polynucleotide, a peptide, an oligopeptide,a polypeptide, a protein and/or an enzyme. The invention is ofparticular use in the fields of molecular biology, structural biology,cell biology, molecular switches, molecular circuits, and molecularcomputational devices, and the manufacture thereof. The invention may beused for characterizing the sequence of a polynucleotide. The inventionalso relates to methods for identifying drug candidates that may be usedto treat, alleviate, or prevent a clinical disorder or disease and tomethods of using compositions so identified to treat a subjectsusceptible to, at risk of contracting or having a disease such ascancer, autoimmune diseases, cell cycle disorders, or other disorders.

2. Background

The invention relates to the field of compositions, methods, andapparatus for characterizing polynucleotides, other polymers, and drugcandidates.

Determining the nucleotide sequence of DNA and RNA in a rapid manner isa major goal of researchers in biotechnology, especially for projectsseeking to obtain the sequence of entire genomes of organisms. Inaddition, rapidly determining the sequence of a polynucleotide isimportant for identifying genetic mutations and polymorphisms inindividuals and populations of individuals.

Nanopore sequencing is one method of rapidly determining the sequence ofpolynucleotide molecules. Nanopore sequencing is based on the propertyof physically sensing the individual nucleotides (or physical changes inthe environment of the nucleotides (that is, for example, an electriccurrent)) within an individual polynucleotide (for example, DNA and RNA)as it traverses or translocates through a nanopore aperture. Inprinciple, the sequence of a polynucleotide can be determined from asingle molecule. However, in practice, it is preferred that apolynucleotide sequence be determined from a statistical average of dataobtained from multiple passages of the same molecule or the passage ofmultiple molecules having the same polynucleotide sequence. The use ofmembrane channels to characterize polynucleotides as the molecules passthrough the small ion channels has been studied by Kasianowicz et al.(Proc. Natl. Acad. Sci. USA. 93:13770-13773, 1996, incorporate herein byreference) by using an electric field to force single stranded RNA andDNA molecules through a 1.5 nanometer diameter nanopore aperture (forexample, an ion channel) in a lipid bilayer membrane. The diameter ofthe nanopore aperture permitted only a single strand of a polynucleotideto traverse the nanopore aperture at any given time. As thepolynucleotide traversed the nanopore aperture, the polynucleotidepartially blocked the nanopore aperture, resulting in a transientdecrease of ionic current. Since the length of the decrease in currentis directly proportional to the length of the polynucleotide,Kasianowicz et al. (1996) were able to determine experimentally lengthsof polynucleotides by measuring changes in the ionic current.

Baldarelli et al. (U.S. Pat. No. 6,015,714) and Church et al. (U.S. Pat.No. 5,795,782) describe the use of nanopores to characterizepolynucleotides including DNA and RNA molecules on a monomer by monomerbasis. In particular, Baldarelli et al. characterized and sequenced thepolynucleotides by passing a polynucleotide through the nanoporeaperture. The nanopore aperture is imbedded in a structure or aninterface, which separates two media. As the polynucleotide passesthrough the nanopore aperture, the polynucleotide alters an ioniccurrent by blocking the nanopore aperture. As the individual nucleotidespass through the nanopore aperture, each base/nucleotide alters theionic current in a manner that allows the identification of thenucleotide transiently blocking the nanopore aperture, thereby allowingone to characterize the nucleotide composition of the polynucleotide andperhaps determine the nucleotide sequence of the polynucleotide.

One disadvantage of previous nanopore analysis techniques is controllingthe rate at which the target polynucleotide is analyzed. As described byKasianowicz, et al. (1996), nanopore analysis is a useful method forperforming length determinations of polynucleotides. However, thetranslocation rate is nucleotide composition dependent and can rangebetween 10⁵ to 10⁷ nucleotides per second under the measurementconditions outlined by Kasianowicz et al. (1996). Therefore, thecorrelation between any given polynucleotide's length and itstranslocation time is not straightforward. It is also anticipated that ahigher degree of resolution with regard to both the composition andspatial relationship between nucleotide units within a polynucleotidecan be obtained if the translocation rate is substantially reduced.

There is currently a need to provide compositions and methods that canbe used in characterization of polymers, including polynucleotides andpolypeptides, characterization of drug candidates, as well as diagnosisand prognosis of diseases and disorders.

BRIEF DESCRIPTION OF THE INVENTION

The invention provides thin film nanopore devices and methods for usingthe same. The subject devices comprise cis and trans chambers connectedby an electrical communication means. The cis and trans chambers areseparated by a thin film comprising at least one pore or channel. In oneembodiment, the chamber comprises a medium, wherein the medium isselected from the group consisting of an aqueous medium, a non-aqueousmedium, an organic medium, and a gel medium. In one preferredembodiment, the thin film comprises a compound having a hydrophobicdomain and a hydrophilic domain. In a more preferred embodiment, thethin film comprises a phospholipid. The devices further comprise a meansfor applying an electric field between the cis and the trans chambers.The pore or channel is shaped and sized having dimensions suitable forpassaging a polymer. In one preferred embodiment the pore or channelaccommodates a part but not all of the polymer. In one other preferredembodiment, the polymer is a polynucleotide. In an alternative preferredembodiment, the polymer is a polypeptide. Other polymers provided by theinvention include polypeptides, phospholipids, polysaccharides, andpolyketides.

In one embodiment, the thin film further comprises a compound having abinding affinity for the polymer. In one preferred embodiment thebinding affinity (K_(a)) is at least 10⁶ l/mole. In a more preferredembodiment the K_(a) is at least 10⁸ l/mole. In yet another embodimentthe compound is adjacent to at least one pore. In an alternativeembodiment, the compound is a soluble compound in the medium. In a morepreferred embodiment the compound is a channel. In a yet more preferredembodiment the channel has biological activity. In a most preferredembodiment, the compound comprises the pore.

In one embodiment the compound comprises a molecule having biologicalactivity. In a preferred embodiment, the molecule is, for example, butnot limited to, a protein, a polypeptide, a peptide, a carbohydrate, alipid, a nucleic acid, a glycopeptide, a glycolipid, a phospholipid, asteroid, a flavanoid, an isoprenoid, a catecholamine, a statin, and thelike. In another embodiment the molecule is a polynucleotide-bindingprotein, such as a transcription factor, a nuclear hormone receptor, aheteronuclear protein, or a ribosome. The polynucleotide-binding proteinmay be used to identify drug candidates or drug targets that enhance orthat may inhibit biding of the protein to the polynucleotide. In anotherembodiment the compound comprises enzyme activity. The enzyme activitycan be, for example, but not limited to, enzyme activity of proteases,kinases, phosphatases, hydrolases, oxidoreductases, isomerases,transferases, methylases, acetylases, ligases, lyases, and the like. Ina more preferred embodiment the enzyme activity can be enzyme activityof DNA polymerase, RNA polymerase, endonuclease, exonuclease, DNAligase, DNase, uracil-DNA glycosidase, ribosomes, kinase, phosphatase,methylase, acetylase, or the like.

In another embodiment the pore is sized and shaped to allow passage ofan activator, wherein the activator is selected from the groupconsisting of ATP, NAD⁺, NADP⁺, diacylglycerol, phosphatidylserine,eicosinoids, retinoic acid, calciferol, ascorbic acid, neuropeptides,enkephalins, endorphins, 4-aminobutyrate (GABA), 5-hydroxytryptamine(5-HT), catecholamines, acetyl CoA, S-adenosylmethionine, and any otherbiological activator.

In yet another embodiment the pore is sized and shaped to allow passageof a cofactor, wherein the cofactor is selected from the groupconsisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, and any otherbiological cofactor.

In a preferred embodiment the pore or channel is a pore molecule or achannel molecule and comprises a biological molecule, or a syntheticmodified molecule, or altered biological molecule, or a combinationthereof. Such biological molecules are, for example, but not limited to,an ion channel, a nucleoside channel, a peptide channel, a sugartransporter, a synaptic channel, a transmembrane receptor, such as GPCRsand the like, a nuclear pore, synthetic variants, chimeric variants, orthe like. In one preferred embodiment the biological molecule isα-hemolysin.

In an alternative, the compound comprises non-enzyme biologicalactivity. The compound having non-enzyme biological activity can be, forexample, but not limited to, proteins, peptides, antibodies, antigens,nucleic acids, peptide nucleic acids (PNAs), locked nucleic acids(LNAs), morpholinos, sugars, lipids, glycophosphoinositols,lipopolysaccharides or the like. The compound can have antigenicactivity. The compound can have selective binding properties whereby thepolymer binds to the compound under a particular controlledenvironmental condition, but not when the environmental conditions arechanged. Such conditions can be, for example, but not limited to, changein [H⁺], change in environmental temperature, change in stringency,change in hydrophobicity, change in hydrophilicity, or the like.

In another embodiment, the invention provides a compound, wherein thecompound further comprises a linker molecule, the linker moleculeselected from the group consisting of a thiol group, a sulfide group, aphosphate group, a sulfate group, a cyano group, a piperidine group, anFmoc group, and a Boc group.

In one embodiment the thin film comprises a plurality of pores. In oneembodiment the device comprises a plurality of electrodes.

Polymers

In another embodiment, the invention provides a method for controllingbinding of a compound, such as a drug composition, a drug candidate, alipid, an oligonucleotide, a polynucleotide, a peptide, an oligopeptide,a polypeptide, a protein to a polymer, the method comprising: providingtwo separate, adjacent pools of a medium and an interface between thetwo pools, the interface having a channel so dimensioned as to allowsequential monomer-by-monomer passage from one pool to the other pool ofonly one polymer at a time; providing a compound having binding activityto a polymer; introducing the polymer into one of the two pools;introducing the enzyme into one of the two pools; applying a potentialdifference between the two pools, thereby creating a first polarity;reversing the potential difference a first time, thereby creating asecond polarity; reversing the potential difference a second time tocreate the first polarity, thereby controlling the binding of the enzymeto the polymer. In a preferred embodiment, the medium is electricallyconductive. In a more preferred embodiment, the medium is an aqueoussolution. In another preferred embodiment, the method further comprisesthe steps of measuring the electrical current between the two pools;comparing the electrical current value (I₁) obtained at the first timethe first polarity was induced with the electrical current value (I₂)obtained at the time the second time the first polarity was induced; anddetermining the difference between I₁ and I₂ thereby obtaining adifference value dI. In another preferred embodiment the method furthercomprises the steps of measuring the electrical current between the twopools; comparing the electrical current value (I₁) obtained at the firsttime the first polarity was induced with the electrical current value(I₂) obtained at a later time and determining the difference between I₁and I₂ thereby obtaining a difference value dI. In one preferredembodiment the compound is a protein. In a more preferred embodiment theprotein is an enzyme. In a more preferred embodiment, the enzyme isselected from the group consisting of proteases, kinases, phosphatases,hydrolases, oxidoreductases, isomerases, transferases, methylases,acetylases, ligases, and lyases. In another alternative embodiment, themethod further comprises the steps of providing reagents that initiateenzyme activity; introducing the reagents to the pool comprising thepolynucleotide complex; and incubating the pool at a suitabletemperature. In a more preferred embodiment, the reagents are selectedfrom the group consisting of an activator and a cofactor. In a yet morepreferred embodiment, the activator is introduced into the pool prior tointroducing the cofactor. In a yet still further more preferredembodiment, the activator is selected from the group consisting of ATP,NAD⁺, NADP⁺, diacylglycerol, phosphatidylserine, eicosinoids, retinoicacid, calciferol, ascorbic acid, neuropeptides, enkephalins, endorphins,4-aminobutyrate (GABA), 5-hydroxytryptamine (5-HT), catecholamines,acetyl CoA, and S-adenosylmethionine. In another still more preferredembodiment, the cofactor is selected from the group consisting of Mg²⁺,Mn²⁺, Ca²⁺, ATP, NAD⁺, and NADP⁺. In another more preferred embodiment,the polymer is selected from the group consisting of polynucleotides,polypeptides, phospholipids, polysaccharides, and polyketides. In oneembodiment the enzyme is introduced into the same pool as the polymer.In an alternative embodiment, the enzyme is introduced into the oppositepool.

In another preferred embodiment the protein is a ligand receptor. In amore preferred embodiment the protein is a ligand receptor selected fromthe group consisting of nuclear receptors, such as, but not limited to,retinoic acid receptors (for example RAR, RXR) and the like, thyroidhormone receptors and the like, steroid hormone receptors and the like,peroxisome-proliferator activated receptors or the like, isoprenoidalcohol (for example, farnesol) receptors and the like, and orphanreceptors and the like.

In another embodiment the ligand is selected from the group consistingof ligands of receptor proteins, such as, but not limited to, steroidhormones such as androgens, estrogens, progesterones, cortisols, and thelike, arachidonic acid derivatives such as eicosenoids, retinoic acidand their derivatives, ethanolamides, thyroid hormones, isoprenoids,statins, small peptide hormones such as endorphins, GnRH, TSH, TRH, LH,or FSH, neurotransmitters such as chatecholamines, acetylcholine,4-aminobutyrate, 5-hydroxytryptamine, glutamate, histamine, aspartate,antigens, domains involved in protein-protein interaction, such as PDZdomains, RDG domains, leucine zipper domains, insulin/ILR domains, MHCclass I and MHC class II/TRC domains, EGF domains, plekstrin domains,domains involved in modified residue/protein interactions, such as SH2and SH3 domains, and the like.

In another embodiment the invention provides a method for detecting aligand that binds to a polymer, whereby the bound ligand to theprotein-polymer holoplex is detected by relative proximity of theligand-holoplex to the channel as disclosed herein. In an alternativeembodiment the protein may be attached to another surface using a linkermolecule or linker moiety, such as in a well surface, whereby presenceof a blocking molecule that binds to the polymer prevents or inhibitsbinding of a ligand-protein complex to the polymer; removal of theblocking molecule allows binding of the ligand-protein complex to atarget polynucleotide, and binding of the ligand to the protein andsubsequence binding to the polymer occurs only in the absence of theblocking molecule. In a preferred embodiment the ligand is a drugtarget. In a more preferred embodiment the ligand is a drug target foruse in the treatment of a clinical disorder or disease as disclosedbelow.

In other embodiments the ligand that binds to the polymer is not aprotein but is a small molecule such as a co-factor or a nucleoside,such as ATP, NAD⁺, and NADP⁺. In other embodiments the ligand that bindsto the polymer is a nucleotide, an oligonucleotide or polynucleotidesuch as a miRNA, an as RNA, poly(ADP)ribose, or a pseudogene product.

Polynucleotides

In another embodiment, the invention provides a method for controllingbinding of compound, such as a drug composition, a drug candidate, alipid, an oligonucleotide, a polynucleotide, a peptide, an oligopeptide,a polypeptide, a protein or an enzyme to a partially double-strandedpolynucleotide complex, the method comprising: providing two separate,adjacent pools of a medium and an interface between the two pools, theinterface having a channel so dimensioned as to allow sequentialmonomer-by-monomer passage from one pool to the other pool of only onepolynucleotide at a time; providing a compound having binding activityto a partially double-stranded polynucleotide complex; providing apolynucleotide complex comprising a first polynucleotide and a secondpolynucleotide, wherein a portion of the polynucleotide complex isdouble-stranded, and wherein the first polynucleotide further comprisesa moiety that is incompatible with the second polynucleotide;introducing the polynucleotide complex into one of the two pools;introducing the compound into one of the two pools; applying a potentialdifference between the two pools, thereby creating a first polarity;reversing the potential difference a first time, thereby creating asecond polarity; reversing the potential difference a second time tocreate the first polarity, thereby controlling the binding of thecompound to the partially double-stranded polynucleotide complex. In apreferred embodiment, the medium is electrically conductive. In a morepreferred embodiment, the medium is an aqueous solution. In a preferredembodiment, the moiety is selected from the group consisting ofacridine, a peptide nucleic acid, a 2′-O-methyl group, a fluorescentcompound, DAPI, a derivatized nucleotide, and a nucleotide isomer. Inanother preferred embodiment, the method further comprises the steps ofmeasuring the electrical current between the two pools; comparing theelectrical current value obtained at the first time the first polaritywas induced with the electrical current value obtained at the time thesecond time the first polarity was induced. In another preferredembodiment the method further comprises the steps of measuring theelectrical current between the two pools; comparing the electricalcurrent value obtained at the first time the first polarity was inducedwith the electrical current value obtained at a later time. In apreferred embodiment, the compound is a protein. In a more preferredembodiment the protein is an enzyme. In a most preferred embodiment, theenzyme is selected from the group consisting of DNA polymerase, RNApolymerase, endonuclease, exonuclease, DNA ligase, DNase, uracil-DNAglycosidase, kinase, phosphatase, methylase, and acetylase. In anotheralternative embodiment, the method further comprises the steps ofproviding at least one reagent that initiates enzyme activity;introducing the reagent to the pool comprising the polynucleotidecomplex; and incubating the pool at a suitable temperature. In a morepreferred embodiment, the reagent is selected from the group consistingof a deoxyribonucleotide and a cofactor. In a yet more preferredembodiment, the deoxyribonucleotide is introduced into the pool prior tointroducing the cofactor. In another still more preferred embodiment,the cofactor is selected from the group consisting of Mg²⁺, Mn²⁺, Ca²⁺,ATP, NAD⁺, and NADP⁺. In one embodiment the enzyme is introduced intothe same pool as the polynucleotide. In an alternative embodiment, theenzyme is introduced into the opposite pool.

In yet another alternative embodiment the protein is a ligand receptor.In a more preferred embodiment the protein is a ligand receptor selectedfrom the group consisting of nuclear receptors, such as, but not limitedto, retinoic acid receptors (for example RAR, RXR) and the like, thyroidhormone receptors and the like, steroid hormone receptors and the like,peroxisome-proliferator activated receptors or the like, isoprenoidalcohol (for example, farnesol) receptors and the like, and orphanreceptors and the like. Other proteins, for example proteins thatinteract with DNA or RNA, for example, transcriptional regulators,transcriptional enhancers, or methylases or demthylases, are well knownto those of skill in the art. Many such proteins are known by those ofskill in the art to have a role in disease or disorders, such as canceror inflammatory disorders.

In another alternative embodiment, the protein can be a ribosome or aribosomal protein; the protein can be a nucleotide binding protein suchas a heteronuclear ribonucleoprotein complex, a small nuclearribonucleoparticle, a polynucleotide transport protein, such as proteinsthat export RNA from the nucleus; the protein can be a viral protein ora bacterial protein, or the like.

Polypeptides

In another embodiment, the invention provides a method for controllingbinding of compound, such as a drug composition, a drug candidate, alipid, an oligonucleotide, a polynucleotide, a peptide, an oligopeptide,a polypeptide, a protein or an enzyme to a polypeptide, the methodcomprising: providing two separate, adjacent pools of a medium and aninterface between the two pools, the interface having a channel sodimensioned as to allow sequential monomer-by-monomer passage from onepool to the other pool of only one polypeptide at a time; providingcompound having binding activity to a polypeptide; providing apolypeptide comprising a modifiable amino acid residue or a moiety;introducing the polypeptide into one of the two pools; introducing thecompound into one of the two pools; applying a potential differencebetween the two pools, thereby creating a first polarity; reversing thepotential difference a first time, thereby creating a second polarity;reversing the potential difference a second time to create the firstpolarity, thereby controlling the binding of the compound to thepolypeptide. In a preferred embodiment, the medium is electricallyconductive. In a more preferred embodiment, the medium is an aqueoussolution. In a preferred embodiment, the moiety is selected from thegroup consisting of a peptide nucleic acid, a 2′-O-methyl group, afluorescent compound, a derivatized amino acid, and a amino acid isomer.In another preferred embodiment, the method further comprises the stepsof measuring the electrical current between the two pools; comparing theelectrical current value obtained at the first time the first polaritywas induced with the electrical current value obtained at the time thesecond time the first polarity was induced. In another preferredembodiment the method further comprises the steps of measuring theelectrical current between the two pools; comparing the electricalcurrent value obtained at the first time the first polarity was inducedwith the electrical current value obtained at a later time. In apreferred embodiment, the compound is a protein. In a more preferredembodiment the protein is an enzyme. In a most preferred embodiment, theenzyme is selected from the group consisting of, protease, kinase,phosphatase, hydrolase, oxidoreductase, isomerase, transferase,methylase, ligase, lyase, lipase, and acetylase. In another alternativeembodiment, the method further comprises the steps of providing at leastone reagent that initiates enzyme activity; introducing the reagent tothe pool comprising the polynucleotide complex; and incubating the poolat a suitable temperature. In a more preferred embodiment, the reagentis selected from the group consisting of an activator and a cofactor. Ina most preferred embodiment, the activator is selected from the groupconsisting of ATP, NAD⁺, NADP⁺, diacylglycerol, phosphatidylserine,acetyl CoA, and S-adenosylmethionine. In a yet more preferredembodiment, the activator is introduced into the pool prior tointroducing the cofactor. In another still more preferred embodiment,the cofactor is selected from the group consisting of Mg²⁺, Mn²⁺, Ca²⁺,ATP, NAD⁺, and NADP⁺. In one embodiment the enzyme is introduced intothe same pool as the polypeptide. In an alternative embodiment, theenzyme is introduced into the opposite pool.

In yet another alternative embodiment the protein is a ligand receptor.In a more preferred embodiment the protein is a ligand receptor selectedfrom the group consisting of nuclear receptors, such as, but not limitedto, receptors for retinoic acid (for example, receptors such as, RAR andRXR) and the like, thyroid hormone (for example, T3 and T4) and thelike, steroid hormones such as androgens, estrogens, progesterones,cortisols, and the like, peroxisome-proliferator activated receptors orthe like, isoprenoid alcohols (for example, farnesol) receptors and thelike, and orphan receptors and the like, ligands of receptor proteins,such as, but not limited to, arachidonic acid derivatives such aseicosenoids and their derivatives, ethanolamides, small peptide hormonessuch as endorphins, GnRH, TSH, TRH, LH, or FSH, neurotransmitters suchas chatecholamines, acetylcholine, 4-aminobutyrate, 5-hydroxytryptamine,glutamate, histamine, aspartate, antigens, domains involved inprotein-protein interaction, such as PDZ domains, RDG domains, leucinezipper domains, insulin/ILR domains, MHC class I and MHC class II/TRCdomains, EGF domains, plekstrin domains, domains involved in modifiedresidue/protein interactions, such as SH2 and SH3 domains, othertranscription factors, other enhancer factors, and the like.

The invention herein disclosed provides for devices and methods that canregulate the rate at which an individual polymer in a mixture is actedupon by another compound, for example, an enzyme. The devices andmethods are also used to determine the nucleotide base sequence of apolynucleotide The invention is of particular use in the fields ofmolecular biology, structural biology, cell biology, molecular switches,molecular circuits, and molecular computational devices, and themanufacture thereof.

In one alternative embodiment, the invention provides a method forcontrolling binding of compound, such as a drug composition, a drugcandidate, a lipid, an oligonucleotide, a polynucleotide, a peptide, anoligopeptide, a polypeptide, a protein or an enzyme to a partiallydouble-stranded polynucleotide complex and the method resulting inidentifying the sequence of a polynucleotide, the method comprising thesteps of: providing two separate adjacent pools comprising a medium, aninterface between the two pools, the interface having a channel sodimensioned as to allow sequential monomer-by-monomer passage from thecis-side of the channel to the trans-side of the channel of only onepolynucleotide strand at a time; providing a compound having bindingactivity to a partially double-stranded polynucleotide complex;providing at least one protected deoxyribonucleotide, the protectioncomprising using a protecting moiety; providing an annealing agent;providing a polynucleotide complex comprising a first polynucleotide anda second polynucleotide, wherein a portion of the polynucleotide complexis double-stranded and a portion is single-stranded; introducing thepolynucleotide complex into one of the two pools; applying a potentialdifference between the two pools, thereby creating a first polarity, thefirst polarity causing the single stranded portion of the polynucleotideto transpose through the channel to the trans-side; introducing thecompound and the protected deoxyribonucleotide into the same pool;introducing the annealing agent into the other pool; allowing theannealing agent to bind to the single-stranded polynucleotide; allowingthe compound and the protected deoxyribonucleotide to bind to thepolynucleotide; allowing the protected deoxyribonucleotide to beincorporated into the polynucleotide; reversing the potential differencea first time, thereby creating a second polarity; allowing the protecteddeoxyribonucleotide to release the protecting moiety and becomedeprotected; measuring the abundance of the protecting moiety; reversingthe potential difference a second time to create the first polarity;repeating any one of the steps, thereby controlling the binding of thecompound to the double-stranded polynucleotide complex and determiningthe sequence of the polynucleotide. In a preferred embodiment, themedium is electrically conductive. In a more preferred embodiment, themedium is an aqueous medium. In one preferred embodiment, the moiety isselected from the group consisting of acridine, a peptide nucleic acid,a 2′-O-methyl group, a fluorescent compound, DAPI, anthocyanins, greenfluorescent protein (GFP), β-glucuronidase, luciferase, Cy3, Cy5, aderivatized nucleotide, and a nucleotide isomer. In another preferredembodiment, the enzyme is selected from the group consisting of DNApolymerase, RNA polymerase, endonuclease, exonuclease, DNA ligase,DNase, uracil-DNA glycosidase, kinase, phosphatase, methylase, andacetylase. In one alternative embodiment, the method further comprisesthe steps of measuring the electrical current between the two pools;comparing the electrical current value obtained at the first time thefirst polarity was induced with the electrical current value obtained atthe time the second time the first polarity was induced. In anotheralternative embodiment, the method further comprises the steps ofmeasuring the electrical current between the two pools; comparing theelectrical current value obtained at the first time the first polaritywas induced with the electrical current value obtained at a later time.In a preferred embodiment, the compound is a protein. In a morepreferred embodiment the protein is an enzyme. In a yet furtheralternative embodiment, the method further comprises the steps ofproviding at least one reagent that initiates enzyme activity;introducing the reagent to the pool comprising the polynucleotidecomplex; and incubating the pool at a temperature sufficient to maintainenzyme activity. In a preferred embodiment, the reagent is a cofactor.In a more preferred embodiment, the cofactor is selected from the groupconsisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, andS-adenosylmethionine. In another preferred embodiment, the protecteddeoxyribonucleotide comprises a deoxyribonucleotide selected from thegroup consisting of dATP, dGTP, dTTP, dCTP, and dUTP. In another morepreferred embodiment, the reagent is selected from the group consistingof ddATP, ddGTP, ddTTP, ddCTP, and ddUTP. In a yet other preferredembodiment, the aqueous medium of at least one pool comprises anannealing agent. In a more preferred embodiment, the annealing agentselected from the group consisting of a complementary oligonucleotideand streptavidin.

The invention also provides a method for sensing the position of amolecule relative to a pore, the method comprising: providing twoseparate, adjacent pools of a medium and a structure between the twopools, the structure having an ion-permeable pore; providing a polyion;providing a molecule having binding activity to the polyion; introducingthe polyion into one of the two pools; introducing the molecule into thesame pool; applying a potential difference between the two pools,thereby creating a first polarity; measuring a first electrical currentbetween the two pools, thereby sensing the position of a moleculerelative to the pore. In a preferred embodiment, the molecule is amacromolecule, wherein the macromolecule selected from the groupconsisting of proteases, kinases, phosphatases, hydrolases,oxidoreductases, isomerases, transferases, methylases, acetylases,ligases, lyases, a transmembrane receptor, a receptor tyrosine kinase, aT-cell receptor, an MHC receptor, and a nuclear receptor. In anotherpreferred embodiment the medium is electrically conductive. In a morepreferred embodiment, the medium is an aqueous solution. In anotherpreferred embodiment, the structure further comprises a compound,wherein the compound is selected from the group consisting of a thiolgroup, a sulfide group, a phosphate group, a sulfate group, a cyanogroup, a piperidine group, an Fmoc group, and a Boc group, siliconnitride, bifunctional alkyl sulfide, and gold. In another preferredembodiment, the polyion is selected from the group consisting ofpolynucleotides, polypeptides, phospholipids, polysaccharides, andpolyketides. In alternative embodiment, the method further comprises thesteps of reversing the potential difference a first time, therebycreating a second polarity; reversing the potential difference a secondtime to create the first polarity, measuring a second electrical currentbetween the two pools, thereby further sensing the position of themolecule relative to the pore. In another alternative embodiment, themethod further comprises the steps of measuring the electrical currentbetween the two pools; comparing the electrical current value obtainedat the first time the first polarity was induced with the electricalcurrent value obtained at a later time. In a still further alternativeembodiment, the method further comprises the steps of providing reagentsthat initiate enzyme activity; introducing the reagents to the poolcomprising the polynucleotide complex; and incubating the pool at asuitable temperature. In a more preferred embodiment, the reagents areselected from the group consisting of an activator and a cofactor. Inanother more preferred embodiment, the activator is introduced into thepool prior to introducing the cofactor. In a still more preferredembodiment, the activator is selected from the group consisting of ATP,NAD⁺, NADP⁺, diacylglycerol, phosphatidylserine, eicosinoids, glycosylphosphatidyl inositols, glycophosphoinositols, lipopolysaccharides,retinoic acid, calciferol, ascorbic acid, neuropeptides, enkephalins,endorphins, 4-aminobutyrate (GABA), 5-hydroxytryptamine (5-HT),catecholamines, acetyl CoA, and S-adenosylmethionine. In another stillmore preferred embodiment, the cofactor is selected from the groupconsisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, and NADP⁺.

In a preferred embodiment the pore or channel comprises a biologicalmolecule, or a synthetic modified or altered biological molecule. Suchbiological molecules are, for example, but not limited to, an ionchannel, such as a-hemolysin, a nucleoside channel, a peptide channel, asugar transporter, a synaptic channel, a transmembrane receptor, such asGPCRs, a receptor tyrosine kinase, and the like, a T-cell receptor, anMHC receptor, a nuclear receptor, such as a steroid hormone receptor, anuclear pore, or the like.

In an alternative embodiment, the compound comprises non-enzymebiological activity. The compound having non-enzyme biological activitycan be, for example, but not limited to, proteins, peptides, antibodies,antigens, nucleic acids, peptide nucleic acids (PNAs), locked nucleicacids (LNAs), morpholinos, sugars, lipids, glycosyl phosphatidylinositols, glycophosphoinositols, lipopolysaccharides, or the like. Thecompound can have antigenic activity. The compound can have ribozymeactivity. The compound can have selective binding properties whereby thepolymer binds to the compound under a particular controlledenvironmental condition, but not when the environmental conditions arechanged. Such conditions can be, for example, but not limited to, changein [H⁺], change in environmental temperature, change in stringency,change in hydrophobicity, change in hydrophilicity, or the like.

In one embodiment the macromolecule comprises enzyme activity. Theenzyme activity can be, for example, but not limited to, enzyme activityof proteases, kinases, phosphatases, hydrolases, oxidoreductases,isomerases, transferases, methylases, acetylases, ligases, lyases, andthe like. In a more preferred embodiment the enzyme activity can beenzyme activity of DNA polymerase, RNA polymerase, endonuclease,exonuclease, DNA ligase, DNase, uracil-DNA glycosidase, kinase,phosphatase, methylase, acetylase, glucose oxidase, or the like. In analternative embodiment, the macromolecule can comprise more that oneenzyme activity, for example, the enzyme activity of a cytochrome P450enzyme. In another alternative embodiment, the macromolecule cancomprise more than one type of enzyme activity, for example, mammalianfatty acid synthase. In another embodiment the macromolecule comprisesribozyme activity.

In an alternative embodiment, the macromolecule comprises non-enzymebiological activity. The macromolecule having non-enzyme biologicalactivity can be, for example, but not limited to, proteins, peptides,antibodies, antigens, nucleic acids, peptide nucleic acids (PNAs),locked nucleic acids (LNAs), morpholinos, sugars, phospholipids, lipids,glycosyl phosphatidyl inositols, glycophosphoinositols,lipopolysaccharides, or the like. The macromolecule can havepolynucleotide-binding activity and/or polypeptide biosynthesisactivity, such as, but not limited to, a ribosome or a nucleosome. Themacromolecule can have antigenic activity. The macromolecule can haveselective binding properties whereby the polymer binds to themacromolecule under a particular controlled environmental condition, butnot when the environmental conditions are changed. Such conditions canbe, for example, but not limited to, change in [H⁺], change inenvironmental temperature, change in stringency, change inhydrophobicity, change in hydrophilicity, or the like.

In another embodiment, the invention provides a compound, wherein thecompound further comprises a linker molecule, the linker moleculeselected from the group consisting of a thiol group, a sulfide group, aphosphate group, a sulfate group, a cyano group, a piperidine group, anFmoc group, and a Boc group. In another embodiment the compound isselected from the group consisting of a bifunctional alkyl sulfide andgold.

In one embodiment the thin film comprises a plurality of pores. In oneembodiment the device comprises a plurality of electrodes.

The invention also provides a finite state machine that can be used todetect and control binding of a molecule to a polymer. In oneembodiment, the molecule is a protein. In a preferred embodiment, theprotein is an enzyme. In one embodiment, the finite state machine candetect a polymer compound having a structural element that inhibitstransposition of the polymer compound through a nanopore. In onepreferred embodiment, the finite state machine can detect a polymercompound comprising a DNA hairpin structure in a nanopore, eject thecompound comprising a DNA hairpin or DNA duplex structure from ananopore after it has been detected but prior to unzipping the hairpinor DNA duplex structure. In an alternative embodiment the polymercompound comprises a derivatized nucleic acid. In yet anotheralternative embodiment, the polymer compound comprises a peptide nucleicacid.

In one embodiment the finite state machine can control binding of amolecule to a polymer at a rate of between about 5 Hz and 2000 Hz. Thefinite state machine can control binding of a molecule to a polymer at,for example, about 5 Hz, at about 10 Hz, at about 15 Hz, at about 20 Hz,at about 25 Hz, at about 30 Hz, at about 35 Hz, at about 40 Hz, at about45 Hz, at about 50 Hz, at about 55 Hz, at about 60 Hz, at about 65 Hz,at about 70 Hz, at about 75 Hz, at about 80 Hz, at about 85 Hz, at about90 Hz, at about 95 Hz, at about 100 Hz, at about 110 Hz, at about 120Hz, at about 125 Hz, at about 130 Hz, at about 140 Hz, at about 150 Hz,at about 160 Hz, at about 170 Hz, at about 175 Hz, at about 180 Hz, atabout 190 Hz, at about 200 Hz, at about 250 Hz, at about 300 Hz, atabout 350 Hz, at about 400 Hz, at about 450 Hz, at about 500 Hz, atabout 550 Hz, at about 600 Hz, at about 700 Hz, at about 750 Hz, atabout 800 Hz, at about 850 Hz, at about 900 Hz, at about 950 Hz, atabout 1000 Hz, at about 1125 Hz, at about 1150 Hz, at about 1175 Hz, atabout 1200 Hz, at about 1250 Hz, at about 1300 Hz, at about 1350 Hz, atabout 1400 Hz, at about 1450 Hz, at about 1500 Hz, at about 1550 Hz, atabout 1600 Hz, at about 1700 Hz, at about 1750 Hz, at about 1800 Hz, atabout 1850 Hz, at about 1900 Hz, at about 950 Hz, and at about 2000 Hz.In a preferred embodiment, the finite state machine can control bindingof a molecule to a polymer at a rate of between about 25 Hz and about250 Hz. In a more preferred embodiment the finite state machine cancontrol binding of a molecule to a polymer at a rate of between about 45Hz and about 120 Hz. In a most preferred embodiment the finite statemachine can control binding of a molecule to a polymer at a rate ofabout 50 Hz.

The invention can be used to determine the nucleotide sequence of apolynucleotide. The invention can also be used to determine the relativeaffinity of an enzyme for binding a polynucleotide, thereby using theinvention to identify novel enzyme compounds that bind topolynucleotides.

In one embodiment the compound comprises enzyme activity. The enzymeactivity can be, for example, but not limited to, enzyme activity ofproteases, kinases, phosphatases, hydrolases, oxidoreductases,isomerases, transferases, methylases, acetylases, ligases, lyases, andthe like. In a more preferred embodiment the enzyme activity can beenzyme activity of DNA polymerase, RNA polymerase, endonuclease,exonuclease, DNA ligase, DNase, uracil-DNA glycosidase, kinase,phosphatase, methylase, acetylase, or the like.

In another embodiment the pore or channel is sized and shaped to allowpassage of an activator, wherein the activator is selected from thegroup consisting of ATP, NAD⁺, NADP⁺, and any other biologicalactivator.

In yet another embodiment the pore or channel is sized and shaped toallow passage of a cofactor, wherein the cofactor is selected from thegroup consisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, and any otherbiological cofactor.

In a preferred embodiment the pore or channel comprises a biologicalmolecule, or a synthetic modified or altered biological molecule. Suchbiological molecules are, for example, but not limited to, an ionchannel, a nucleoside channel, a peptide channel, a sugar transporter, asynaptic channel, a transmembrane receptor, such as GPCRs and the like,a nuclear pore, or the like. In one preferred embodiment the biologicalmolecule is α-hemolysin.

In an alternative, the compound comprises non-enzyme biologicalactivity. The compound having non-enzyme biological activity can be, forexample, but not limited to, proteins, peptides, antibodies, antigens,nucleic acids, peptide nucleic acids (PNAs), locked nucleic acids(LNAs), morpholinos, sugars, lipids, glycophosphoinositols,lipopolysaccharides, or the like. The compound can have antigenicactivity. The compound can have selective binding properties whereby thepolymer binds to the compound under a particular controlledenvironmental condition, but not when the environmental conditions arechanged. Such conditions can be, for example, but not limited to, changein [H⁺], change in environmental temperature, change in stringency,change in hydrophobicity, change in hydrophilicity, or the like.

In yet another embodiment, the invention provides a method forcontrolling binding of compound, such as a drug composition, a drugcandidate, a lipid, an oligonucleotide, a polynucleotide, a peptide, anoligopeptide, a polypeptide, a protein or an enzyme to a polynucleotideusing voltage feedback control, the method resulting in repeated captureof and dissociation of the compound by the polynucleotide, the methodcomprising the steps of: providing two separate adjacent compartmentscomprising a medium, an interface between the two compartments, theinterface having a channel so dimensioned as to allow sequentialmonomer-by-monomer passage from the cis-side of the channel to thetrans-side of the channel of only one polynucleotide strand at a time;providing a compound having binding activity for a polynucleotide;providing a protected ribonucleotide; providing a polynucleotide-bindingcompound; providing a polynucleotide complex, wherein a portion of thepolynucleotide complex is double-stranded and a portion issingle-stranded; introducing the polynucleotide complex into one of thetwo chambers; applying a potential difference between the two chambers,thereby creating a first polarity, the first polarity causing the singlestranded portion of the polynucleotide to transpose through the channelto the trans-side; introducing the protected ribonucleotide into thesame chamber; introducing the compound into the same chamber; allowingthe compound to bind to the polynucleotide; allowing the protectedribonucleotide to bind to the polynucleotide; measuring the electricalcurrent through the channel thereby detecting the binding of thecompound and the protected ribonucleotide to the polynucleotide;introducing the polynucleotide-binding compound into the other of thetwo chambers; decreasing the potential difference a first time, therebycreating a second polarity; allowing the polynucleotide-binding compoundto bind to the single-stranded polynucleotide; reversing the potentialdifference, thereby creating a third polarity; reversing the potentialdifference a second time; measuring the electrical current through thechannel, thereby detecting a polynucleotide alone or a polynucleotidebound to the compound and the protected ribonucleotide; repeating anyone of the steps, thereby controlling the binding of the compound to thepolynucleotide. In a preferred embodiment, the method further comprisesthe steps of measuring the electrical current between the two chambers;comparing the electrical current value obtained at the first time thefirst polarity was induced with the electrical current value obtained atthe time the second time the first polarity was induced. In anotherpreferred embodiment, the method further comprises the steps ofmeasuring the electrical current between the two chambers; comparing theelectrical current value obtained at the first time the first polaritywas induced with the electrical current value obtained at a later time.In a preferred embodiment, the polynucleotide-binding compound isselected from the group consisting of an oligonucleotide complementaryto the polynucleotide, a peptide nucleic acid, a locked nucleic acid, aderivatized nucleotide, and a nucleotide isomer. In another preferredembodiment, the compound is a protein. In a more preferred embodimentthe protein is an enzyme. In most preferred embodiment, the enzyme isselected from the group consisting of DNA polymerase, RNA polymerase,endonuclease, exonuclease, DNA ligase, DNase, uracil-DNA glycosidase,kinase, phosphatase, methylase, and acetylase. In another preferredembodiment the medium is electrically conductive. In another preferredembodiment the medium is an aqueous medium. In another preferredembodiment the protected ribonucleotide comprises a deoxyribonucleotideselected from the group consisting of dATP, dGTP, TTP, dCTP, UTP, anddUTP. In another embodiment the protected ribonucleotide is selectedfrom the group consisting of ATP, GTP, TTP, CTP, and tRNA.

The method may further comprise the steps of providing at least onereagent that initiates enzyme activity; introducing the reagent to thechamber comprising the polynucleotide complex; and incubating thechamber at a temperature sufficient to maintain enzyme activity. In apreferred embodiment the reagent is a cofactor. In a more preferredembodiment, the cofactor is selected from the group consisting of Mg²⁺,Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, and S-adenosylmethionine. In anotherpreferred embodiment, the reagent is selected from the group consistingof ddATP, ddGTP, ddTTP, ddCTP, and ddUTP.

In another embodiment of the invention, the invention provides a methodfor controlling binding of compound, such as a drug composition, a drugcandidate, a lipid, an oligonucleotide, a polynucleotide, a peptide, anoligopeptide, a polypeptide, a protein or an enzyme to a polynucleotideusing voltage feedback control, the method resulting in identifying thesequence of a polynucleotide, the method comprising the steps of:providing two separate adjacent chambers comprising a medium, aninterface between the two chambers, the interface having a channel sodimensioned as to allow sequential monomer-by-monomer passage from thecis-side of the channel to the trans-side of the channel of only onepolynucleotide strand at a time; providing a compound having bindingactivity for a polynucleotide; providing a protecteddeoxyribonucleotide; providing a polynucleotide-binding compound;providing a polynucleotide complex, wherein a portion of thepolynucleotide complex is double-stranded and a portion issingle-stranded; introducing the polynucleotide complex into one of thetwo chambers; applying a potential difference between the two chambers,thereby creating a first polarity, the first polarity causing the singlestranded portion of the polynucleotide to transpose through the channelto the trans-side; introducing the protected deoxyribonucleotide intothe same chamber; introducing the compound into the same chamber;allowing the compound to bind to the polynucleotide; allowing theprotected deoxyribonucleotide to bind to the polynucleotide; measuringthe electrical current through the channel thereby detecting the bindingof the compound and the protected deoxyribonucleotide to thepolynucleotide; introducing the polynucleotide-binding compound into theother of the two chambers; decreasing the potential difference a firsttime, thereby creating a second polarity; allowing thepolynucleotide-binding compound to bind to the single-strandedpolynucleotide; reversing the potential difference, thereby creating athird polarity; reversing the potential difference a second time;measuring the electrical current through the channel, thereby detectinga polynucleotide alone or a polynucleotide bound to the compound and theprotected deoxyribonucleotide; repeating any one of the steps, therebycontrolling the binding of the compound to the polynucleotide. In apreferred embodiment, the method further comprises the steps ofmeasuring the electrical current between the two chambers; comparing theelectrical current value obtained at the first time the first polaritywas induced with the electrical current value obtained at the time thesecond time the first polarity was induced. In another preferredembodiment, the method further comprises the steps of measuring theelectrical current between the two chambers; comparing the electricalcurrent value obtained at the first time the first polarity was inducedwith the electrical current value obtained at a later time. In apreferred embodiment, the polynucleotide-binding compound is selectedfrom the group consisting of an oligonucleotide complementary to thepolynucleotide, a peptide nucleic acid, a locked nucleic acid, aderivatized nucleotide, and a nucleotide isomer. In another preferredembodiment, the compound is a protein. In a more preferred embodimentthe protein is an enzyme. In a most preferred embodiment, the enzyme isselected from the group consisting of DNA polymerase, RNA polymerase,endonuclease, exonuclease, DNA ligase, DNase, uracil-DNA glycosidase,kinase, phosphatase, methylase, and acetylase. In another preferredembodiment the medium is electrically conductive. In another preferredembodiment the medium is an aqueous medium. In another preferredembodiment the protected deoxyribonucleotide comprises adeoxyribonucleotide selected from the group consisting of dATP, dGTP,TTP, dCTP, UTP, and dUTP. The method may further comprise the steps ofproviding at least one reagent that initiates enzyme activity;introducing the reagent to the chamber comprising the polynucleotidecomplex; and incubating the chamber at a temperature sufficient tomaintain enzyme activity. In a preferred embodiment the reagent is acofactor. In a more preferred embodiment, the cofactor is selected fromthe group consisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, andS-adenosylmethionine. In another preferred embodiment, the reagent isselected from the group consisting of ddATP, ddGTP, ddTTP, ddCTP, andddUTP.

The invention also provides a method for controlling movement of apolynucleotide using voltage feedback control, the method resulting inidentifying the sequence of a polynucleotide, the method comprising thesteps of: providing two separate adjacent chambers comprising a medium,an interface between the two chambers, the interface comprising amaterial having at least one channel therethrough and wherein onechamber is on the cis-side of the interface and the other chamber is onthe trans-side of the interface, the channel so dimensioned as to allowsequential monomer-by-monomer passage from the cis-side of the channelto the trans-side of the channel of only one polynucleotide strand at atime; providing an enzyme having binding activity for a polynucleotide;providing a blocking oligomer; providing a polynucleotide complex,wherein a portion of the polynucleotide complex is double-stranded and aportion is single-stranded; providing a complimentary oligomer, whereinthe complimentary oligomer is complementary to a portion of the singlestranded polynucleotide; providing a substrate; introducing thepolynucleotide complex into one of the two chambers; introducing theblocking oligomer into the same chamber; allowing the blocking oligomerto bind to the polynucleotide complex; introducing the enzyme into thesame chamber; introducing the complementary oligomer into the otherchamber; applying a potential difference between the two chambers,thereby creating a first polarity, the first polarity causing the singlestranded portion of the polynucleotide to transpose through the channelto the trans-side thereby stripping the blocking oligomer from thepolynucleotide complex; measuring the electrical current through thechannel thereby detecting the polynucleotide; decreasing the potentialdifference a first time, thereby creating a second polarity; allowingthe complementary oligomer to bind to the single-strandedpolynucleotide; reversing the potential difference, thereby creating athird polarity; providing conditions to allow the enzyme to bind to thepolynucleotide complex; providing conditions to allow the enzyme toincorporate substrate into the polynucleotide, thereby increasing lengthof the double-stranded portion; reversing the potential difference asecond time; measuring the electrical current through the channel,thereby detecting a polynucleotide having incorporated substrate or apolynucleotide bound to the enzyme; repeating any one of the steps,thereby controlling the synthesis of the polynucleotide. In onepreferred embodiment there are a plurality of channels. In anotherpreferred embodiment the blocking oligomer is selected from the groupconsisting of an oligonucleotide having partial complementarity to aportion of the polynucleotide complex. In a more preferred embodimentthe oligonucleotide having partial complementarity to a portion of thepolynucleotide complex further comprises a duplex structure at one endof the oligonucleotide and a blocking moiety at the other end of theoligonucleotide. In another more preferred embodiment theoligonucleotide having partial complementarity to a portion of thepolynucleotide complex further comprises a hairpin loop structure at oneend of the oligonucleotide. In an alternative embodiment the blockingmoiety is selected from the group consisting of acridine, a peptidenucleic acid, a 2′-O-methyl group, a fluorescent compound, DAPI, ananthocyanin, green fluorescent protein (GFP), β-glucuronidase,luciferase, Cy3, Cy5, a derivatized nucleotide, and a nucleotide isomer.In another alternative embodiment the blocking moiety blocks the bindingof the compound, protein, and/or enzyme to the polynucleotide complex.In yet another alternative embodiment the blocking moiety blocks thebiological activity of the compound, protein, and/or enzyme upon thepolynucleotide complex. In still another alternative embodiment theblocking moiety blocks the strand displacement within the polynucleotidecomplex. In still yet another alternative embodiment the blocking moietyblocks replication and/or extension of the strand within thepolynucleotide complex. In another embodiment the complementary oligomeris selected from the group consisting of an oligonucleotidecomplementary to the polynucleotide, a peptide nucleic acid, a lockednucleic acid, a derivatized nucleotide, a nucleotide isomer, and a DNAaptamer. In a preferred embodiment the enzyme is selected from the groupconsisting of DNA polymerase, RNA polymerase, endonuclease, exonuclease,DNA ligase, DNase, uracil-DNA glycosidase, topoisomerase, telomerase,DNA-repair enzyme; DNA-handling enzyme, helicase, primase, gyrase,kinase, phosphatase, methylase, acetylase, histone, transcriptionfactor, and ribosome. In an alternative embodiment the step of allowingthe blocking oligomer to bind to the polynucleotide complex is performedprior to introducing the polynucleotide complex and the blockingoligomer into the same chamber, and is followed by a step of introducingthe polynucleotide complex and the blocking oligomer into the chamber.In another embodiment the method further comprises the steps ofproviding at least one reagent that initiates enzyme activity;introducing the reagent to the chamber comprising the polynucleotidecomplex; and incubating the chamber at a temperature sufficient tomaintain enzyme activity. In a preferred embodiment the reagent is acofactor. In a more preferred embodiment the cofactor is selected fromthe group consisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺, NADP⁺, andS-adenosylmethionine. In a preferred embodiment the medium iselectrically conductive. In another preferred embodiment the medium isan aqueous medium. In a preferred embodiment the substrate comprises adeoxyribonucleotide selected from the group consisting of dATP, dGTP,TTP, dCTP, UTP, and dUTP. In another embodiment the substrate comprisesa ribonucleotide selected from the group consisting of ATP, GTP, TTP,CTP, and tRNA.

In a preferred embodiment the method controls the synthesis of apolynucleotide, the method resulting in identifying the sequence of apolynucleotide.

The invention also provides a polynucleotide sequencing systemcomprising (a) a structure comprising an ion-permeable passageconnecting a first chamber and a second chamber, wherein apolynucleotide to be sequenced is placed with a blocking oligomer in thefirst chamber; (b) an enzyme having a binding affinity for apolynucleotide of at least 10⁶ M⁻¹·s⁻¹ (c) a electronic power source forcreating a potential difference between the two chambers; (d) adetection system operative to detect a property of a the polynucleotidemoving relative to the ion-permeable passage. In one embodiment thestructure further comprises a lipid bilayer. In another embodiment theblocking oligomer binds to the polynucleotide to be sequenced understringent conditions. In a yet further embodiment the enzyme is selectedfrom the group consisting of DNA polymerase, RNA polymerase,endonuclease, exonuclease, DNA ligase, DNase, uracil-DNA glycosidase,topoisomerase, telomerase, DNA-repair enzyme; DNA-handling enzyme,helicase, primase, gyrase, kinase, phosphatase, methylase, acetylase,histone, transcription factor, and ribosome. In a further embodiment theproperty of the polynucleotide is that of base identity at the 3′ end ofthe double-stranded portion of the polynucleotide.

The invention also provides a blocking oligomer, wherein the blockingoligomer comprises a single stranded oligonucleotide, the singlestranded oligonucleotide comprising a duplex structure at one end of theoligonucleotide and a blocking moiety at the other end of theoligonucleotide. In one embodiment a portion of the blocking oligomerfurther comprises a non-oligonucleotide composition wherein thenon-oligonucleotide composition is selected from the group consisting ofa polymer, a monomer, a dimer, a multimer, an acid, a base, an organiccompound, and an inorganic compound. In one preferred embodiment, thenon-oligonucleotide composition permits efficient removal of theblocking oligomer from a polynucleotide to which a portion of theblocking oligonucletide is bound or to which it is hybridized. Inanother embodiment the blocking moiety is selected from the groupconsisting of acridine, a peptide nucleic acid, a 2′-O-methyl group, afluorescent compound, DAPI, an anthocyanin, green fluorescent protein(GFP), β-glucuronidase, luciferase, Cy3, Cy5, a derivatized nucleotide,and a nucleotide isomer. In another embodiment the blocking oligomerbinds to a polynucleotide to be sequenced under stringent conditions. Ina preferred embodiment the blocking oligomer comprises between about 5and 30 nucleotides. In a more preferred embodiment the blocking oligomercomprises between about 15 and 25 nucleotides.

In one embodiment the thin film comprises a plurality of pores. In oneembodiment the device comprises a plurality of electrodes.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an embodiment of the invention whereby enzyme bindingto a polynucleotide is prevented by a blocking oligomer.

FIG. 2 illustrates an embodiment of the invention whereby enzymecatalytic activity upon a polynucleotide is prevented by a blockingoligomer.

FIG. 3 illustrates an embodiment of the invention whereby enzymecatalytic activity upon a polynucleotide is activated by injection ofMg²⁺ across the nanopore.

FIG. 4 illustrates an embodiment of the invention showing a method forsequencing single polynucleotide molecules.

FIG. 5 illustrates an embodiment of the invention showing an alternativemethod for sequencing single polynucleotide molecules.

FIG. 6 illustrates a flow chart disclosing the system of one embodimentof the invention.

FIG. 7 illustrates a single α-hemolysin protein channel (mushroom shape)inserted into lipid bilayer. Under applied potential (trans-sidepositive), K⁺ ions flow to the cis side, and Cl— ions flow to the transside. The vestibule and stem of the pore channel are shown.

FIG. 8 illustrates a schematic of nanopore and DNA (top), and plot ofrepresentative ionic current signal (bottom) during a 20 base pairhairpin DNA translocation event under 180 mV applied potential. (I) At180 mV, KCl ions pass through the open channel resulting in ˜64 pAcurrent. (II) Upon capture of the single-stranded end of the DNAmolecule into the cis opening of the pore, the flow of ions is reducedto ˜20 pA. (III) After ˜5 msec, the voltage unzips the hairpin, causingssDNA to pass through the pore into the trans chamber, completing themeasured blockaded event. The duration of the event is referred to asdwell time.

FIG. 9 illustrates means for distinguishing DNA, DNA/KF complexes, orDNA/KF/dNTP complexes in the nanopore device. FIG. 9A depictstranslocation through the nanopore of DNA alone (14 bp hairpin with a 36nucleotide 5′ overhang and 2′-3′ dideoxycytidine terminus, template baseat n=0 is C), while translocation of the 14 bphp from complexes with KF,or from complexes with KF and dGTP, are shown in FIGS. 9B and 9C,respectively. For each of FIGS. 9A, 9B and 9C, a diagram of the nanoporewith the associated complex (I), a current trace (II), and a dwell timeevent plot (III) are presented. In IV, probability histograms of thebase 10 logarithm of dwell time data are shown in solid. Closeexamination of the event plot in FIG. 9C(III) reveals that most longdwell time events are within 22 to 24 pA. An open bar subset histogramfor the events within 22 to 24 pA is overlaid on probability histogram(FIG. 9C(IV)), revealing that the chosen range is dominated by longdwell time events.

FIG. 10 illustrates tethering of a captured DNA oligomer by annealing atrans-side primer. (a) The finite-state machine (FSM) monitors the openchannel current for translocation events. (b) Captured molecule causesthe current to attenuate, and the FSM diagnoses an event (DNA orDNA/KF/dGTP) based on the threshold [15.75, 26.75] pA. (c) Upon eventdiagnosis, the FSM reduces the applied voltage to 50 mV for 20 sec,during which time the 20mer primer anneals to the 5′ end. The graphicshows a close up of the lower half of nanopore, with the 5′ end and20mer primer in the trans chamber.

FIG. 11 illustrates a time course of ionic current signal in tetheredDNA experiment. First 2 seconds shows the end of the 20 sec tetheringwaiting period (50 mV applied) for 5′-end primer to anneal in transchamber. Fishing time of t_(fish)=5 seconds used, with nine probe eventsshown. Probe event number 5 is blown-up to show details of anenzyme-bound event, with terminal step and subsequent terminal stepdiagnosis after 1.13 msec. Since enzyme-bound events last ˜100 msec, thecontrol logic is primarily in fishing mode in this experiment.

FIG. 12 illustrates fishing and probing of tethered DNA molecule in ananopore. (a) Fishing mode, with t_(fish)=0.521 sec. (b) Probing mode,in which the FSM applies 150 mV until a DNA alone event is diagnosedwith threshold [7.5, 15.5] pA. In the event shown, DNA alone isdiagnosed as soon as the transient settles, with no enzyme bound to theDNA, and the fishing mode is restarted. (c) Fishing mode.

FIG. 13 illustrates another method for fishing and probing of tetheredDNA molecule in a nanopore. (a) Fishing mode, with t_(fish)=0.521 sec.(b) Probing mode, in which the FSM applies 150 mV until a DNA aloneevent is diagnosed. In the event shown, enzyme-bound DNA is diagnosed,and the FSM continues to monitor the filtered amplitude. (c) Theterminal step is diagnosed, using the [7.5, 15.5] pA threshold, and thefishing phase is restarted. (d) Fishing mode.

FIG. 14 illustrates a proposed mechanism for translocation of DNA/KFbinary complex and DNA/KF/dGTP ternary complex through a nanopore. (a)Shows a typical current trace when ternary complex is present. Parts(a)(i), (a)(ii), and (a)(iii) illustrate the configuration of the systemfor each section of the signal. (b) and (c) show a dwell time event plotfor a 14 bphp alone and the terminal step present in ternary complexevents, respectively. The similarity of the dwell times in the two plotssupports the perception that the terminal step is a result of KFdissociation. (d) and (e) show the same as (b) and (c) but for a 20bphp. (f) shows a DNA only event (f)(i) and a DNA/KF binary event(f)(ii) side by side. Note the absence of the terminal step in the DNAonly event when compared to the enzyme-bound event.

FIG. 15 illustrates a representative ternary complex event under FPGAcontrol. (a)(i) The FPGA diagnosed an enzyme event in the detectionrange [17.2 pA, 22.8 pA]. a(ii) The FPGA continued to monitor thecurrent to ensure it stayed within the detection range for at least 20msec. Events lasting longer than 20 msec were diagnosed as a DNA/KF/dGTPternary complex event. (a)(iii) Upon diagnosis of a ternary complex, theFPGA reversed the voltage to −50 mV for 5 ms, ejecting the complex fromthe pore. The 180 mV capture voltage was then restored. (b) Dwell timeprobability histograms for 24±2.8 pA events with FPGA control (527 totalevents in red) and without FPGA control (155 total events in blue).

FIG. 16 illustrates regulation of 20 base pair hairpin (bphp) dwell timeusing FSM control. (I) The red current signals are low-pass filtered at5 kHz, the blue signal is a mean filtered current, and the red voltagesignal is the commanded voltage. Typical events and correspondingvoltage signals under (a) constant 180 mV voltage, (b) dwell timeextension control, and (c) dwell time aggregation control. (II) Eventplot of DNA events, showing average amplitude vs. dwell time for eachevent. (III) Probability histograms of the base 10 logarithm of dwelltime for all events (filled bars), and for subset of events in range 13to 18 pA (open bars).

FIG. 17 illustrates repeated KF binding events using a singlepolynucleotide oligomer. FIG. 17A shows steps (a)-(c), and FIG. 17Bshows step (d). (a) Captured hairpin or hairpin bound with KF at 180 mV.(b) Hairpin was held in vestibule at 50 mV for trans-side primer toanneal (20 sec). (c) Fished for KF at −20 mV for 5 sec. (d) 180 mVapplied to check for presence of KF. If enzyme binding does not occur,bare DNA was immediately detected in the pore. Otherwise, the FSM waitedfor KF to dissociate, leaving hairpin in vestibule (20 pA terminalstep). In both cases, once bare DNA is present in the pore, the FSMreverses the voltage (−20 mV) before the hairpin unzips to fish foranother KF. Steps (c) through (d) were repeated until the hairpintranslocated.

FIG. 18 illustrates an exemplary embodiment of the invention using ablocking molecule that prevents binding of a polynucleotide by aDNA-binding molecule. A strategy is shown for restricting DNA synthesisto individual DNA substrate molecules captured in a nanopore usingblocking oligomers.

FIG. 19 illustrates exemplary blocking oligomer structures used toinhibit bulk phase DNA synthesis.

FIG. 20 illustrates blocking oligomer-inhibition of bulk phase primerextension (DNA synthesis) by T7 DNA polymerase (exo-).

FIG. 21 illustrates a result whereby the nanopore device reliablyreports capture of polymerase-DNA-dNTP complexes formed in the bulkphase.

FIG. 22 illustrates evidence using a nanopore that the blockingoligomers prevent T7 DNA polymerase binding in bulk phase.

FIG. 23 shows binding of T7 DNA pol to individual DNA substrates isactivated electronically at the nanopore.

FIG. 24 shows that polymerase-catalyzed nucleotide addition proceeds atthe nanopore following unzipping of the blocking oligomer.

FIG. 25 shows that DNA translocation through the nanopore in real timeis driven by T7 DNA polymerase.

DETAILED DESCRIPTION OF THE INVENTION

The embodiments disclosed in this document are illustrative andexemplary and are not meant to limit the invention. Other embodimentscan be utilized and structural changes can be made without departingfrom the scope of the claims of the present invention.

The invention provides a method for sequencing a polynucleotide withoutthe need for reversible or irreversible incorporation of a terminatornucleotide into the replicated strand. The invention also provides forspecific activation of nucleotide-binding enzymes and/or proteins at ananopore. In particular the invention provides for a feedback control ofthese reactions. The invention may also be used to identify drugcandidates and/or drug targets.

As used herein and in the appended claims, the singular forms “a,” “an,”and “the” include plural reference unless the context clearly dictatesotherwise. Thus, for example, a reference to “a nanopore” includes aplurality of such nanopores, and a reference to “a signal” is areference to one or more signals and equivalents thereof, and so forth.

By “polynucleotide” is meant DNA or RNA, including any naturallyoccurring, synthetic, or modified nucleotide. Nucleotides include, butare not limited to, ATP, dATP, CTP, dCTP, GTP, dGTP, UTP, TTP, dUTP,5-methyl-CTP, 5-methyl-dCTP, ITP, dITP, 2-amino-adenosine-TP,2-amino-deoxyadenosine-TP, 2-thiothymidine triphosphate,pyrrolo-pyrimidine triphosphate, 2-thiocytidine as well as thealphathiotriphosphates for all of the above, and2′-O-methyl-ribonucleotide triphosphates for all the above bases.Modified bases include, but are not limited to, 5-Br-UTP, 5-Br-dUTP,5-F-UTP, 5-F-dUTP, 5-propynyl dCTP, and 5-propynyl-dUTP.

By “transport property” is meant a property measurable during polymermovement with respect to a nanopore. The transport property may be, forexample, a function of the solvent, the polymer, a label on the polymer,other solutes (for example, ions), or an interaction between thenanopore and the solvent or polymer.

The term “ligand” means any composition having a binding affinity foranother molecule and whereby binding of the ligand to the other moleculeresults in an increase or, alternatively, a decrease, in biologicalactivity of the other molecule. Such other molecules may also be termed“ligand receptor”.

A “hairpin structure” is defined as an oligonucleotide having anucleotide sequence that is about 6 to about 100 nucleotides in length,the first half of which nucleotide sequence is at least partiallycomplementary to the second part thereof, thereby causing thepolynucleotide to fold onto itself, forming a secondary hairpinstructure.

A “hairpin shaped precursor” is defined as a hairpin structure that isprocessed by a Microprocessor complex and then by a Dicer enzymecomplex, yielding an oligonucleotide that is about 16 to about 24nucleotides in length.

“Identity” or “similarity” refers to sequence similarity between twopolynucleotide sequences or between two polypeptide sequences, withidentity being a more strict comparison. The phrases “percent identity”and “% identity” refer to the percentage of sequence similarity found ina comparison of two or more polynucleotide sequences or two or morepolypeptide sequences. “Sequence similarity” refers to the percentsimilarity in base pair sequence (as determined by any suitable method)between two or more polynucleotide sequences. Two or more sequences canbe anywhere from 0-100% similar, or any integer value there between.Identity or similarity can be determined by comparing a position in eachsequence that may be aligned for purposes of comparison. When a positionin the compared sequence is occupied by the same nucleotide base oramino acid, then the molecules are identical at that position. A degreeof similarity or identity between polynucleotide sequences is a functionof the number of identical or matching nucleotides at positions sharedby the polynucleotide sequences. A degree of identity of polypeptidesequences is a function of the number of identical amino acids atpositions shared by the polypeptide sequences. A degree of homology orsimilarity of polypeptide sequences is a function of the number of aminoacids at positions shared by the polypeptide sequences.

The term “incompatible” refers to the chemical property of a moleculewhereby two molecules or portions thereof cannot interact with oneanother, physically, chemically, or both. For example, a portion of apolymer comprising nucleotides can be incompatible with a portion of apolymer comprising nucleotides and another chemical moiety, such as forexample, acridine, a peptide nucleic acid, a 2′-O-methyl group, afluorescent compound, DAPI, a derivatized nucleotide, a nucleotideisomer, or the like. In another example, a portion of a polymercomprising amino acid residues can be incompatible with a portion of apolymer comprising amino acid residues and another chemical moiety, suchas, for example, a sulfate group, a phosphate group, an acetyl group, acyano group, a piperidine group, a fluorescent group, a sialic acidgroup, a mannose group, or the like.

“Alignment” refers to a number of DNA or amino acid sequences aligned bylengthwise comparison so that components in common (such as nucleotidebases or amino acid residues) may be visually and readily identified.The fraction or percentage of components in common is related to thehomology or identity between the sequences. Alignments may be used toidentify conserved domains and relatedness within these domains. Analignment may suitably be determined by means of computer programs knownin the art, such as MACVECTOR software (1999) (Accelrys, Inc., SanDiego, Calif.).

The terms “highly stringent” or “highly stringent condition” refer toconditions that permit hybridization of DNA strands whose sequences arehighly complementary, wherein these same conditions excludehybridization of significantly mismatched DNAs. Polynucleotide sequencescapable of hybridizing under stringent conditions with thepolynucleotides of the present invention may be, for example, variantsof the disclosed polynucleotide sequences, including allelic or splicevariants, or sequences that encode orthologs or paralogs of presentlydisclosed polypeptides. Polynucleotide hybridization methods aredisclosed in detail by Kashima et al. (1985) Nature 313: 402-404, andSambrook et al. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed.,Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (“Sambrook”);and by Haymes et al., “Nucleic Acid Hybridization: A PracticalApproach”, IRL Press, Washington, D.C. (1985), which references areincorporated herein by reference.

In general, stringency is determined by the incubation temperature,ionic strength of the solution, and concentration of denaturing agents(for example, formamide) used in a hybridization and washing procedure(for a more detailed description of establishing and determiningstringency, see below). The degree to which two nucleic acids hybridizeunder various conditions of stringency is correlated with the extent oftheir similarity. Thus, similar polynucleotide sequences from a varietyof sources, such as within an organism's genome (as in the case ofparalogs) or from another organism (as in the case of orthologs) thatmay perform similar functions can be isolated on the basis of theirability to hybridize with known peptide-encoding sequences. Numerousvariations are possible in the conditions and means by whichpolynucleotide hybridization can be performed to isolate sequenceshaving similarity to sequences known in the art and are not limited tothose explicitly disclosed herein. Such an approach may be used toisolate polynucleotide sequences having various degrees of similaritywith disclosed sequences, such as, for example, sequences having 60%identity, or more preferably greater than about 70% identity, mostpreferably 72% or greater identity with disclosed sequences.

Devices that can be used to carry out the methods of the instantinvention are described in for example, U.S. Pat. No. 5,795,782, U.S.Pat. No. 6,015,714, U.S. Pat. No. 6,267,872, U.S. Pat. No. 6,362,002,U.S. Pat. No. 6,746,594, U.S. Pat. No. 6,428,959, U.S. Pat. No.6,617,113, U.S. Pat. No. 7,189,503, and in copending patent applicationU.S. Ser. No. 12/080,684, filed 4 Apr. 2008 and PCT/US08/00467, filed 4Apr. 2008, each of which is hereby incorporated by reference in theirentirety. The invention is best understood by the examples and methodsdisclosed herein.

It is now understood that a means to control the time at which enzymaticactivity begins for an individual polymer in a mixture would be anadvantage. That is, absent such a control, initiation of enzyme activity(for example by addition of Mg²⁺ cofactor to a bath containing enzymeand DNA) would begin at once and that enzyme-polynucleotide complexeswould necessarily be at many points along the target strands whencaptured by the nanopore in a time series. At least five methods can beused to overcome these potential multiple interactions:

a) Microfluidics.

A factor for inducing enzyme activity may be added only after anenzyme-polynucleotide complex is captured by the pore. After thatpolynucleotide is processed, the bath can be flushed and a newpopulation of polynucleotide targets added absent the inducing factor.The cycle is then repeated.

b) Protein Engineering.

By covalently linking an enzyme to a pore, it can be possible to haveonly one enzyme in the system and it will be immediately adjacent to thepore (some methods to achieve this are articulated in U.S. applicationSer. No. 10/739,585).

c) Block Activity of Enzymes in Bulk Phase Using an Agent Released Onlyby Capture of a Complex in the Nanopore.

This is illustrated by examples in the figures (FIGS. 1 and 2) anddescribed herein.

Assume a DNA primer-template pair (at about 1 μM) in a solution thatcontains all required dNTPs (at about 200 μM each), Mg²⁺ (at about 5mM), and a processive DNA polymerase (at about 1 μM). The solution is incontact with a single nanopore (for example, α-hemolysin) with anapplied voltage such that negatively charged DNA is drawn into the pore.Each primer-template pair is also annealed to a sequence specificmolecule at (or close to) the first base that will be added to theprimer strand (position n=0). This molecule may have any of numerousstructures but will likely be PNA or 2′-O-methyl substituted DNA in theearly trials. This blocking molecule either inhibits binding of thepolymerase at the initiation site (FIG. 1) or it allows binding butprevents strand synthesis (FIG. 2). The blocking molecule includes aloop that is sufficiently large that it cannot enter the nanopore. Thus,when the strand is pulled into the pore under applied voltage, this loopis hung-up at the pore orifice. This initiates unzipping of the blockfrom the primer template and the blocking molecule dissociates.Polymerase binding and polymerase-catalyzed strand synthesis can follow.The point of this method is that only the strand captured by thenanopore is unlocked from the blocking molecule at the instant it is tobe examined. When optimized, a 100 μl volume containing 1 μM of DNAprimer/template represents one nanopore-activated molecule in 6×10¹³molecules total.

In an alternative scenario, a blocking molecule, such as a blockingoligomer, may be used to prevent (block) interaction of the DNA templateor polynucleotide complex with a binding molecule. The binding moleculemay be a compound, such as, but not limited to, a drug composition, adrug candidate, a protein, a peptide, or an enzyme, for example. Theblocking oligomer may comprise a blocking moiety at one end of themolecule wherein the blocking moiety interacts with the DNA template orpolynucleotide complex to prevent binding of the binding molecule to theDNA template or polynucleotide complex. It may block the biologicalactivity of binding molecule upon the DNA template or polynucleotidecomplex. It may block the strand displacement within the DNA template orpolynucleotide complex. It may block replication and/or extension of thestrand within the DNA template or polynucleotide complex. In some cases,it may be preferred to use a blocking oligomer that comprises severalmoieties, each of which may interact with the DNA template orpolynucleotide complex by different means and wherein the blockingoligomer comprises less than 50% of complementary nucleotides. In somecircumstances it may desirable for the blocking oligomer to comprise ahairpin loop structure that may alter the binding affinity of a bindingmolecule to the DNA template or polynucleotide complex. Alternatively,it may be desirable for the blocking primer to comprise a duplexstructure that may alter the interaction between a binding molecule tothe DNA template or polynucleotide complex. The blocking oligomer mayalternatively comprise an oligonucleotide that it not complementary to apolynucleotide to be sequenced. The blocking oligomer may alsoalternatively comprise a non-oligonucleotide composition whereby thenon-oligonucleotide cannot interact with a polynucleotide to besequenced. These alternative compositions are useful in use to permitefficient removal of the blocking oligomer from a polynucleotide towhich it is bound.

d) Deliver a Cofactor Through the Pore from the Trans-Side to theCis-Side (Containing Enzyme).

This can effectively restrict the required factor to the volumeimmediately adjacent to the pore. An example is Mg²⁺. This isillustrated by examples in the figure (FIG. 3) and described herein.

An example of this approach is illustrated in FIG. 3. Mg²⁺ is aco-factor essential for catalytic activity by many DNA and/or RNAmodifying enzymes including polynucleotide polymerases. In thisscenario, Mg²⁺ at greater than millimolar concentrations are added tothe trans compartment. The cis compartment comprises all the otherreagents, enzymes, and substrates necessary for catalysis. The ciscompartment also comprises trace concentrations of EDTA (at about 0.1mM) to ensure that free [Mg²⁺] on the cis side is effectively zero inbulk phase. Since Mg²⁺ is a divalent cation under physiologicalconditions, an applied voltage that attracts a polynucleotide into thenanopore (trans side+) would drive Mg²⁺ in the opposite directiontowards the cis compartment. Thus, in the volume (area of medium)immediately adjacent to the pore aperture, the free [Mg²⁺] is a functionof the voltage-driven flux from the trans side to the cis side acrossthe nanopore minus the Mg²⁺ fraction complexed by 0.1 mM EDTA and minusthe rate of Mg²⁺ diffusion away from the volume (area of medium)adjacent to the nanopore aperture. [Mg²⁺] in the bulk volume remainseffectively zero and is dominated by EDTA complexation of divalentmetal(s).

e) Deliver ssDNA Template Through the Pore from the Trans Side to theCis Side Containing Enzyme.

This can effectively restrict enzyme processing of the template to themolecule captured in the pore. All other template strands are isolatedfrom enzymes by the impermeable layer (a bilayer for example) supportingthe channel.

Enzymes that interact with polynucleotides are known to those of skillin the art and can include, but are not limited to, DNA polymerase suchas a DNA polymerase selected from E. coli DNA polymerase I, E. coli DNApolymerase I Large Fragment (Klenow fragment), phage T7 DNA polymerase,Phi-29 DNA polymerase, Thermus aquaticus (Taq) DNA polymerase, Thermusflavus (Tfl) DNA polymerase, Thermus Thermophilus (Tth) DNA polymerase,Thermococcus litoralis (Tli) DNA polymerase, Pyrococcus furiosus (Pfu)DNA polymerase, VENT DNA polymerase, Bacillus stearothermophilus (Bst)DNA polymerase, AMV reverse transcriptase, MMLV reverse transcriptase,and HIV-1 reverse transcriptase, RNA polymerase such as RNA polymeraseselected from T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase,and E. coli RNA polymerase, and an exonuclease such as exonucleaseLambda, T7 Exonuclease, Exo III, RecJ₁ Exonuclease, Exo I, and Exo T.

Nanopore-Coupled Sequencing by Synthesis

This is a technique for sequencing of single DNA molecules. It combinesfeatures of conventional sequencing by synthesis (SBS) with novelnanopore analysis of single DNA molecules under electronic andbiochemical feedback control. It relies upon 3′ terminator technology,specifically reversible terminator technology.

The basic strategy is outlined in FIG. 4 for a single nanopore. Ourlaboratory has developed a strategy to perform this analysis on a chipwith up to 400,000 pores. Design and fabrication of such a chip aredisclosed below.

As illustrated in FIG. 4, A DNA molecule with both doubled-stranded andsingle-stranded segments is captured in a nanoscale pore under anapplied voltage (trans side positive) (Step a: FIG. 4). DNA of thisnature can be generated by timed exonuclease digestion of restrictionfragments from genomic DNA or from BAC clones etc. The nanopore is largeenough to permit translocation of the ssDNA segment, but thedouble-stranded segment cannot translocate because its diameter is toolarge to fit through the narrowest part of the pore. The a-hemolysinpore is ideal for this and is therefore used to illustrate thetechnique. Strand capture and entry of the duplex segment into the porevestibule can be confirmed based on current amplitude. Once this isachieved, the voltage is reduced under feedback control (Step b: FIG.4). At this point, the duplex terminus can be examined and identified byany of several techniques. For example, an earlier patent from thislaboratory demonstrated that duplex termini can be identified based onDC current impedance alone. At the same time, the 5′-end of the ssDNA onthe trans side of the channel is annealed to an agent (for example, acomplementary oligonucleotide or streptavidin) that keeps the strand inthe pore indefinitely.

Once the DNA strand is captured and the terminus identified, the ciscompartment is perfused with a buffer containing Mg²⁺, a DNA polymerase(for example, the Klenow fragment (KF) of DNA polymerase), and each ofthe four dNTPs protected with a distinct reversible terminator or by anidentical reversible terminator (Step c: FIG. 4). The membrane potentialis then reversed thus driving the duplex terminus of the target strandinto the cis compartment containing the polymerase and substrates (Stepc: FIG. 4). Sufficient time is then allowed for the correct protecteddNTP to be added to the target (Step e: FIG. 4). When that time haselapsed, the voltage is reversed once again (trans-side positive (Stepf: FIG. 4). The duplex terminus is pulled next to the pore'slimiting-aperture where the identity of the added nucleotide isestablished. If no protected nucleotide has been added, the signal willbe the same as in Step b. If this is the case, Steps d to f are repeateduntil the correct nucleotide is added and identified. Followingconfirmed addition of the protected nucleotide, the cis compartment isperfused and a deprotecting buffer is added (Step g: FIG. 4).Alternatively, we envision a scenario where a deprotecting agent locatedonly near the nanopore is activated or deactivated under our controlthat would eliminate the need for perfusion. The deprotecting agent maybe an enzyme (for example, alkaline phosphatase), light, or a solute(for example, palladium to catalyze deallylation). After perfusion, atrans-side negative potential is established, driving the duplexterminus into the cis compartment where the reversible terminator can beremoved (Step h: FIG. 4). Following this reaction, a trans-side positivepotential is re-established, drawing the duplex terminus back to thelimiting aperture where it can be examined to determine if deprotectionhas been successfully achieved, and to confirm the identity of the lastbase (Step i: FIG. 4). In the event that deprotection is not successful,steps h and i are repeated. If deprotection was successful, the cycle isrepeated at step b.

The scenario illustrated in FIG. 5 is similar to that illustrated inFIG. 4 except that exonuclease digestion takes place on the trans sideof the channel and the DNA is captured in reverse orientation comparedto FIG. 4. In this strategy, the template strand is held in place on thecis side by the primer from which strand synthesis originates. Theadvantage of this scenario is that ssDNA fed into to the nanopore can begenerated in blocks by a series of timed exonuclease digestions in thetrans compartment. Thus, most of the template would be as dsDNA. Forexample, if the exonuclease cut at 10 ms per base (on average), a 1000base overhang could be generated at the end of a 20 kb dsDNA target.When about 1000 bases were successfully filled in by nanopore-coupledSBS, the exonuclease (or a required cofactor) could be re-added to thetrans compartment and allowed to react for an additional 10 seconds. Thenewly generated ssDNA would be filled in base-by-base in the ciscompartment as before. This would be repeated in approximately tworounds of 1000 bases to complete the 20 kb fragment.

The pore aperture can vary in dimensions, for example it can have adiameter of between about 0.5 nm and 10 nm in size. For example, thediameter can be about 0.5 nm, 1 nm, 1.25 nm, 1.5 nm, 1.75 nm, 2 nm, 2.25nm, 2.5 nm, 2.75 nm, 3 nm, 3.5 nm, 4 nm, 4.5 nm, 5 nm, 6 nm, 7 nm, 8 nm,9 nm, 10 nm, or any dimension there between.

Nanopore-coupled sequencing by synthesis has several advantages overconventional SBS, but the main advantages are these:

1) Nucleotide addition and reversible terminator removal can be directlymeasured on the individual target strand.

2) The system is controlled both electronically and biochemically sothat nucleotide addition and deprotection steps can be repeated rapidlyuntil they are successful.

3) A very long DNA molecule can be captured, manipulated, andquantitatively retained in the pore for an indefinite period.

4) The volume of reagents that are used can be very small (on the orderof 1000, and it is possible that a given volume can be recycled hundredsof times. With further development, it may be possible to controlactivation and deactivation of the deprotection step at the nanoporeorifice. This would completely eliminate the need for perfusion.

As is true with conventional SBS, this assay can be performed inparallel. We envision as many as 400,000 independently addressable poreson a 1 cm×1 cm chip that can be fabricated using conventionallithography (see separate disclosure below).

Here we propose polynucleotides that can be used to place and attachmacromolecules and other polyanions/polycations at the nanoporeaperture. Such macromolecules and polymers can be, for example, apolynucleotide-binding protein, such as, but not limited to apolynucleotide polymerase at the nanopore orifice. A nanopore has theuseful property of bringing virtually any desired macromolecularstructure to a defined site that can be specified by the user. Afterbeing placed at the nanopore site, macromolecular functions can bemonitored by the user in a variety of ways. This method can be appliedto macromolecules such as, but not limited to, enzymes, receptorproteins, ribozymes, and ribosomes. The method can be applied either tobiological pores, or to solid state pores produced in thin inorganicmembranes.

The basis of this invention is that a sufficiently long strand of anionized polymer can be attached to the desired macromolecule, either bycovalent or non-covalent bonds. The polymer is then drawn through thenanopore by an electrical voltage applied across the membrane. In someapplications, it may be necessary to regulate the force on themacromolecule by varying the voltage acting across the pore. As aresult, the macromolecule is placed at the site of the pore withsub-nanometer precision. The macromolecule is then maintained at thepore site either by the electrical force produced by the transmembranevoltage, or by a covalent bond that is engineered between themacromolecule and the pore, or the surface adjacent to the pore. Morethan one macromolecule can be attached in series if desired.

Functions of the single macromolecule can then be monitored byelectrical effects produced at the pore. For instance, the ionic currentthrough the pore can be measured and molecular functions are detected asmodulations of the current. Alternatively, an electrode such as a carbonnanotube is placed across the pore and molecular functions are detectedby modulations of the electronic current through the nanotube.

Exemplary Uses of the Invention

(1) A nanopore device can be used to monitor the turnover of enzymessuch as exonucleases and polymerases, which have important applicationsin DNA sequencing.

(2) A nanopore device can function as a biosensor to monitor theinteraction between soluble substances such as enzyme substrates orsignaling molecules. Examples include blood components such as glucose,uric acid and urea, hormones such as steroids and cytokines, andpharmaceutical agents, such as, for example, statins or b-blockers, thatexert their function by binding to receptor molecules.

(3) A nanopore device can monitor in real time the function of importantbiological structures such as ribosomes, and perform this operation witha single functional unit.

FIG. 6 illustrates a flow chart disclosing the method of using theinvention as manufactured.

Biological nanopores have utility in sequencing of polynucleotides but,due to the low current used (approximately in the tens of picoamps),detection using high-throughput of a single nanopore sequencing devicemay be limited to approximately 1000 base pairs per second.Manufacturing arrays of biological nanopores that can operateindependently of each other, such as used in the manufacture of verylarge arrays of integrated circuits, a very large scale array ofnanopores may perform millions of biochemical reactions and analyses ina single second.

The array elements may be manufactured in a step-wise parallel manner,similar to the manufacture of transistors on integrated circuits. All,or most, of the similar layers of each array element are created in asequence of single process steps that simultaneously take place on all.Or most, of the array elements.

In order that the each of the hundreds of thousands of biologicalnanopore elements may be in communication with one another using aminimum number of wired connections, a serial interface and addressablelogic can be used to multiplex the large amount of data entering andexiting the array (see flowchart on FIG. 6).

The finite state machine can be created using state-of-the-artcommercially available 65 nm process technology, for example from TaiwanSemiconductor Manufacturing Company, Taiwan). A 600×600 array ofnanopores can perform 360,000 biochemical reaction and detection/sensingsteps at a rate of 1000 Hz. This may enable sequencing ofpolynucleotides, for example, to proceed at a rate of 360 million baserper second per 1 cm×1 cm die cut from the semiconductor wafer.

Exemplary means for applying an electric field between the cis- andtrans-chambers are, for example, electrodes comprising an immersed anodeand an immersed cathode, that are connected to a voltage source. Suchelectrodes can be made from, for example silver chloride, or any othercompound having similar physical and/or chemical properties.

Detection

Time-dependent transport properties of the nanopore aperture may bemeasured by any suitable technique. The transport properties may be afunction of the medium used to transport the polynucleotide, solutes(for example, ions) in the liquid, the polynucleotide (for example,chemical structure of the monomers), or labels on the polynucleotide.Exemplary transport properties include current, conductance, resistance,capacitance, charge, concentration, optical properties (for example,fluorescence and Raman scattering), and chemical structure. Desirably,the transport property is current.

Exemplary means for detecting the current between the cis and the transchambers have been described in Astier et al. (2007, Chem. Phys. Chem.8: 2189-2194), WO 00/79257, U.S. Pat. Nos. 646,594, 6,673,615,6,627,067, 6,464,842, 6,362,002, 6,267,872, 6,015,714, and 5,795,782 andU.S. Publication Nos. 2004/0121525, 2003/0104428, and 2003/0104428, andcan include, but are not limited to, electrodes directly associated withthe channel or pore at or near the pore aperture, electrodes placedwithin the cis and the trans chambers, ad insulated glassmicro-electrodes. The electrodes may be capable of, but not limited to,detecting ionic current differences across the two chambers or electrontunneling currents across the pore aperture or channel aperture. Inanother embodiment, the transport property is electron flow across thediameter of the aperture, which may be monitored by electrodes disposedadjacent to or abutting on the nanopore circumference. Such electrodescan be attached to an Axopatch 200B amplifier for amplifying a signal.

Applications and/or uses of the invention disclosed herein may include,but not be limited to the following:

-   -   1. Assay of relative or absolute gene expression levels as        indicated by mRNA, rRNA, and tRNA. This includes natural,        mutated, and pathogenic nucleic acids and polynucleotides.    -   2. Assay of allelic expressions.    -   3. Haplotype assays and phasing of multiple SNPs within        chromosomes.    -   4. Assay of DNA methylation state.    -   5. Assay of mRNA alternate splicing and level of splice        variants.    -   6. Assay of RNA transport.    -   7. Assay of protein-nucleic acid complexes in mRNA, rRNA, and        DNA.    -   8. Assay of the presence of microbe or viral content in food and        environmental samples via DNA, rRNA, or mRNA.    -   9. Identification of microbe or viral content in food and        environmental samples via DNA, rRNA, or mRNA.    -   10. Identification of pathologies via DNA, rRNA, or mRNA in        plants, human, microbes, and animals.    -   11. Assay of nucleic acids in medical diagnosis.    -   12. Quantitative nuclear run off assays.    -   13. Assay of gene rearrangements at DNA and RNA levels,        including, but not limited to those found in immune responses.    -   14. Assay of gene transfer in microbes, viruses and        mitochondria.    -   15. Assay of genetic evolution.    -   16. Forensic assays.    -   17. Drug discovery.        Filtered Derivative for Adaptive Terminal Step Detection Using a        Finite-State Machine (FSM)

Constant voltage experiments with DNA alone and with DNA, Klenowfragment (KF) of DNA polymerase, and complementary dNTP, may be used todetermine the thresholds used for detecting the terminal step, that is,dissociation of KF/dNTP from DNA. A filtered derivative of the ioniccurrent amplitude, in addition to the filtered amplitude, may be used todetect the terminal step. In practice, the filtered amplitude isthresholded as disclosed herein, and the filtered derivative ismonitored for deflections above a set threshold. Preliminary analysisusing the exponentially weighted mean filter has shown that the filteredderivative, applied to the filtered amplitude, deflects by an order ofmagnitude in the presence of the terminal step. Experiments using boththe filtered amplitude and filtered derivative are conducted, tuning thederivative filter and deflection threshold to ensure robust detection ofKF dissociation.

Deflections of the derivative may be monitored for terminal step-leveldeflections, in principle, for any applied voltage in real time using acommon (minimum) deflection threshold. In this approach, terminal stepdetection using only the filtered derivative, and not thresholding ofthe filtered amplitude is tested. Robust detection using only thefiltered derivative may increase the range of voltages that can be usedto probe the DNA for KF binding, without requiring identification offiltered current amplitude ranges for each probing voltage. In additionto monitoring the filtered derivative for deflections, logic thatmonitors the filtered amplitude for relative amplitude changes, withoutusing preset thresholds is developed. The goal is a more adaptive ioniccurrent filtering logic that can robustly detect KF dissociation for abroad range of (possibly varying) probing voltages, using the filteredamplitude and/or filtered derivative, without dependence on presentamplitude thresholds.

Polynucleotides homologous to other polynucleotides may be identified byhybridization to each other under stringent or under highly stringentconditions. Single-stranded polynucleotides hybridize when theyassociate based on a variety of well characterized physical-chemicalforces, such as hydrogen bonding, solvent exclusion, base stacking andthe like. The stringency of a hybridization reflects the degree ofsequence identity of the nucleic acids involved, such that the higherthe stringency, the more similar are the two polynucleotide strands.Stringency is influenced by a variety of factors, including temperature,salt concentration and composition, organic and non-organic additives,solvents, etc. present in both the hybridization and wash solutions andincubations (and number thereof), as described in more detail in thereferences cited above.

Stability of DNA duplexes is affected by such factors as basecomposition, length, and degree of base pair mismatch. Hybridizationconditions may be adjusted to allow DNAs of different sequencerelatedness to hybridize. The melting temperature (T_(m)) is defined asthe temperature when 50% of the duplex molecules have dissociated intotheir constituent single strands. The melting temperature of a perfectlymatched duplex, where the hybridization buffer contains formamide as adenaturing agent, may be estimated by the following equations:T _(m)(° C.)=81.5+16.6(log [Na⁺])+0.41(% G+C)−0.62(%formamide)−500/L  (I) DNA-DNAT _(m)(° C.)=79.8+18.5(log [Na⁺])+0.58(% G+C)+−0.12(% G+C)²−0.5(%formamide)−820/L  (II) DNA-RNAT _(m)(° C.)=79.8+18.5(log [Na⁺])+0.58(% G+C)+0.12(% G+C)²−0.35(%formamide)−820/L  (III) RNA-RNAwhere L is the length of the duplex formed, [Na⁺] is the molarconcentration of the sodium ion in the hybridization or washingsolution, and % G+C is the percentage of (guanine+cytosine) bases in thehybrid. For imperfectly matched hybrids, approximately 1° C. is requiredto reduce the melting temperature for each 1% mismatch.

Hybridization experiments are generally conducted in a buffer of pHbetween pH 6.8 to 7.4, although the rate of hybridization is nearlyindependent of pH at ionic strengths likely to be used in thehybridization buffer (Anderson and Young (1985) “Quantitative FilterHybridisation.” In: Hames and Higgins, editors, Nucleic AcidHybridisation. A Practical Approach. Oxford, IRL Press, 73-111). Inaddition, one or more of the following may be used to reducenon-specific hybridization: sonicated salmon sperm DNA or anothernon-complementary DNA, bovine serum albumin, sodium pyrophosphate,sodium dodecylsulfate (SDS), polyvinyl-pyrrolidone, ficoll, andDenhardt's solution. Dextran sulfate and polyethylene glycol 6000 act toexclude DNA from solution, thus raising the effective probe DNAconcentration and the hybridization signal within a given unit of time.In some instances, conditions of even greater stringency may bedesirable or required to reduce non-specific and/or backgroundhybridization. These conditions may be created with the use of highertemperature, lower ionic strength and higher concentration of adenaturing agent such as formamide.

Stringency conditions can be adjusted to screen for moderately similarfragments such as homologous sequences from distantly related organisms,or to highly similar fragments such as genes that duplicate functionalenzymes from closely related organisms. The stringency can be adjustedeither during the hybridization step or in the post-hybridizationwashes. Salt (for example, NaCl) concentration, formamide concentration,hybridization temperature and probe lengths are variables that can beused to alter stringency (as described by the formula above). As ageneral guidelines high stringency is typically performed at T_(m)−5° C.to T_(m)−20° C., moderate stringency at T_(m)−20° C. to T_(m)−35° C. andlow stringency at T_(m)−35° C. to T_(m)−50° C. for duplex>150 basepairs. Hybridization may be performed at low to moderate stringency(25-50° C. below T_(m)), followed by post-hybridization washes atincreasing stringencies. Maximum rates of hybridization in solution aredetermined empirically to occur at T_(m)−25° C. for DNA-DNA duplex andT_(m)−15° C. for RNA-DNA duplex. Optionally, the degree of dissociationmay be assessed after each wash step to determine the need forsubsequent, higher stringency wash steps.

High stringency conditions may be used to select for polynucleotidesequences with high degrees of identity to the disclosed sequences. Anexample of stringent hybridization conditions obtained in a filter-basedmethod such as a Southern or northern blot for hybridization ofcomplementary nucleic acids that have more than 100 complementaryresidues is about 5° C. to 20° C. lower than the thermal melting point(T_(m)) for the specific sequence at a defined ionic strength and pH.Conditions used for hybridization may include about 0.02 M to about 0.15M sodium chloride, about 0.5% to about 5% casein, about 0.02% SDS orabout 0.1% N-laurylsarcosine, about 0.001 M to about 0.03 M sodiumcitrate, at hybridization temperatures between about 50° C. and about70° C. More preferably, high stringency conditions are about 0.02 Msodium chloride, about 0.5% casein, about 0.02% SDS, about 0.001 Msodium citrate, at a temperature of about 50° C. polynucleotidemolecules that hybridize under stringent conditions will typicallyhybridize to a probe based on either the entire DNA molecule or selectedportions, for example, to a unique subsequence, of the DNA.

Stringent salt concentration will ordinarily be less than about 750 mMNaCl and 75 mM trisodium citrate. Increasingly stringent conditions maybe obtained with less than about 500 mM NaCl and 50 mM trisodiumcitrate, to even greater stringency with less than about 250 mM NaCl and25 mM trisodium citrate. Low stringency hybridization can be obtained inthe absence of organic solvent, for example, formamide, whereas highstringency hybridization may be obtained in the presence of at leastabout 35% formamide, and more preferably at least about 50% formamide.Stringent temperature conditions will ordinarily include temperatures ofat least about 30° C., more preferably of at least about 37° C., andmost preferably of at least about 42° C. with formamide present. Varyingadditional parameters, such as hybridization time, the concentration ofdetergent, for example, sodium dodecyl sulfate (SDS) and ionic strength,are well known to those skilled in the art. Various levels of stringencyare accomplished by combining these various conditions as needed.

The washing steps that follow hybridization may also vary in stringency;the post-hybridization wash steps primarily determine hybridizationspecificity, with the most critical factors being temperature and theionic strength of the final wash solution. Wash stringency can beincreased by decreasing salt concentration or by increasing the washtemperature. Stringent salt concentration for the wash steps willpreferably be less than about 30 mM NaCl and 3 mM trisodium citrate, andmost preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate.

Thus, hybridization and wash conditions that may be used to bind andremove polynucleotides with less than the desired homology to thepolynucleotide sequences or their complements that encode the presenttranscription factors include, for example:

6×SSC at 65° C.;

50% formamide, 4×SSC at 42° C.; or

0.5×SSC, 0.1% SDS at 65° C.;

with, for example, two wash steps of 10-30 minutes each. Usefulvariations on these conditions will be readily apparent to those skilledin the art.

A person of skill in the art would not expect substantial variationamong polynucleotide species encompassed within the scope of the presentinvention because the highly stringent conditions set forth in the aboveformulae yield structurally similar polynucleotides.

If desired, one may employ wash steps of even greater stringency,including about 0.2×SSC, 0.1% SDS at 65° C. and washing twice, each washstep being about 30 min, or about 0.1×SSC, 0.1% SDS at 65° C. andwashing twice for 30 min. The temperature for the wash solutions willordinarily be at least about 25° C., and for greater stringency at leastabout 42° C. Hybridization stringency may be increased further by usingthe same conditions as in the hybridization steps, with the washtemperature raised about 3° C. to about 5° C., and stringency may beincreased even further by using the same conditions except the washtemperature is raised about 6° C. to about 9° C. For identification ofless closely related homologs, wash steps may be performed at a lowertemperature, for example, 50° C.

An example of a low stringency wash step employs a solution andconditions of at least 25° C. in 30 mM NaCl, 3 mM trisodium citrate, and0.1% SDS over 30 min. Greater stringency may be obtained at 42° C. in 15mM NaCl, with 1.5 mM trisodium citrate, and 0.1% SDS over 30 min. Evenhigher stringency wash conditions are obtained at 65° C. to 68° C. in asolution of 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Washprocedures will generally employ at least two final wash steps.Additional variations on these conditions will be readily apparent tothose skilled in the art (for example, in US Patent Application No.20010010913).

Stringency conditions can be selected such that an oligonucleotide thatis perfectly complementary to the coding oligonucleotide hybridizes tothe coding oligonucleotide with at least about a 5-10× higher signal tonoise ratio than the ratio for hybridization of the perfectlycomplementary oligonucleotide to a polynucleotide encoding atranscription factor known as of the filing date of the application. Itmay be desirable to select conditions for a particular assay such that ahigher signal to noise ratio, that is, about 15× or more, is obtained.Accordingly, a subject polynucleotide will hybridize to a unique codingoligonucleotide with at least a 2× or greater signal to noise ratio ascompared to hybridization of the coding oligonucleotide to apolynucleotide encoding known polypeptide. The particular signal willdepend on the label used in the relevant assay, for example, afluorescent label, a colorimetric label, a radioactive label, or thelike. Labeled hybridization or PCR probes for detecting relatedpolynucleotide sequences may be produced by oligolabeling, nicktranslation, end-labeling, or PCR amplification using a labelednucleotide.

Encompassed by the invention are polynucleotide sequences that arecapable of hybridizing to polynucleotides and fragments thereof undervarious conditions of stringency (for example, in Wahl and Berger (1987)Methods Enzymol. 152: 399-407, and Kimmel (1987) Methods Enzymol. 152:507-511). Estimates of homology are provided by either DNA-DNA orDNA-RNA hybridization under conditions of stringency as is wellunderstood by those skilled in the art (Hames and Higgins, Editors(1985) Nucleic Acid Hybridisation: A Practical Approach, IRL Press,Oxford, U.K.). Stringency conditions can be adjusted to screen formoderately similar fragments, such as homologous sequences fromdistantly related organisms, to highly similar fragments, such as genesthat duplicate functional enzymes from closely related organisms.Post-hybridization washes determine stringency conditions.

Exemplary Characterization and Uses of the Invention

Sequencing

In one embodiment, the invention may be used to perform sequenceanalysis of polynucleotides. The analyses have an advantage over theprior art and the current art in that a single analysis may be performedat a single site, thereby resulting in considerable cost savings forreagents, substrates, reporter molecules, and the like. Of additionalimport is the rapidity of the sequencing reaction and the signalgenerated, thereby resulting in an improvement over the prior art.

Other methods for sequencing nucleic acids are well known in the art andmay be used to practice any of the embodiments of the invention. Thesemethods employ enzymes such as the Klenow fragment of DNA polymerase I,SEQUENASE, Taq DNA polymerase and thermostable T7 DNA polymerase(Amersham Pharmacia Biotech, Piscataway N.J.), or combinations ofpolymerases and proofreading exonucleases such as those found in theELONGASE amplification system (Life Technologies, Gaithersburg Md.).Preferably, sequence preparation is automated with machines such as theHYDRA microdispenser (Robbins Scientific, Sunnyvale Calif.), MICROLAB2200 system (Hamilton, Reno Nev.), and the DNA ENGINE thermal cycler(PTC200; MJ Research, Watertown Mass.). Machines used for sequencinginclude the ABI PRISM 3700, 377 or 373 DNA sequencing systems (PEBiosystems), the MEGABACE 1000 DNA sequencing system (Amersham PharmaciaBiotech), and the like. The sequences may be analyzed using a variety ofalgorithms that are well known in the art and described in Ausubel etal. (1997; Short Protocols in Molecular Biology, John Wiley & Sons, NewYork N.Y., unit 7.7) and Meyers (1995; Molecular Biology andBiotechnology, Wiley VCH, New York N.Y., pp. 856-853).

Shotgun sequencing is used to generate more sequence from cloned insertsderived from multiple sources. Shotgun sequencing methods are well knownin the art and use thermostable DNA polymerases, heat-labile DNApolymerases, and primers chosen from representative regions flanking thepolynucleotide molecules of interest. Incomplete assembled sequences areinspected for identity using various algorithms or programs such asCONSED (Gordon (1998) Genome Res. 8: 195-202) that are well known in theart. Contaminating sequences including vector or chimeric sequences ordeleted sequences can be removed or restored, respectively, organizingthe incomplete assembled sequences into finished sequences.

Extension of a Polynucleotide Sequence

The sequences of the invention may be extended using various PCR-basedmethods known in the art. For example, the XL-PCR kit (PE Biosystems),nested primers, and commercially available cDNA or genomic DNA librariesmay be used to extend the polynucleotide sequence. For all PCR-basedmethods, primers may be designed using commercially available software,such as OLIGO 4.06 primer analysis software (National Biosciences,Plymouth Minn.) to be about 22 to 30 nucleotides in length, to have a GCcontent of about 50% or more, and to anneal to a target molecule attemperatures from about 55° C. to about 68° C. When extending a sequenceto recover regulatory elements, it is preferable to use genomic, ratherthan cDNA libraries.

Use of Polynucleotides with the Invention

Hybridization

Polynucleotides and fragments thereof can be used in hybridizationtechnologies for various purposes. A probe may be designed or derivedfrom unique regions such as the 5′ regulatory region or from a conservedmotif such as a receptor signature and used in protocols to identifynaturally occurring molecules encoding the polynucleotide protein,allelic variants, or related molecules. The probe may be DNA or RNA, isusually single stranded and should have at least 50% sequence identityto any of the polynucleotide sequences. Hybridization probes may beproduced using oligolabeling, nick translation, end-labeling, or PCRamplification in the presence of labeled nucleotide. A vector containingthe polynucleotide or a fragment thereof may be used to produce an mRNAprobe in vitro by addition of an RNA polymerase and labeled nucleotides.These procedures may be conducted using commercially available kits suchas those provided by Amersham Pharmacia Biotech.

The stringency of hybridization is determined by G+C content of theprobe, salt concentration, and temperature. In particular, stringencycan be increased by reducing the concentration of salt or raising thehybridization temperature. In solutions used for some membrane basedhybridizations, addition of an organic solvent such as formamide allowsthe reaction to occur at a lower temperature. Hybridization can beperformed at low stringency with buffers, such as 5×SSC with 1% sodiumdodecyl sulfate (SDS) at 60° C., which permits the formation of ahybridization complex between polynucleotide sequences that contain somemismatches. Subsequent washes are performed at higher stringency withbuffers such as 0.2×SSC with 0.1% SDS at either 45° C. (mediumstringency) or 68° C. (high stringency). At high stringency,hybridization complexes will remain stable only where thepolynucleotides are completely complementary. In some membrane-basedhybridizations, preferably 35%, or most preferably 50%, formamide can beadded to the hybridization solution to reduce the temperature at whichhybridization is performed, and background signals can be reduced by theuse of other detergents such as Sarkosyl or Triton X-100 and a blockingagent such as denatured salmon sperm DNA. Selection of components andconditions for hybridization are well known to those skilled in the artand are reviewed in Ausubel (supra) and Sambrook et al. ((1989)Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press,Plainview N.Y.).

Microarrays may be prepared and analyzed using methods known in the art.Oligonucleotides may be used as either probes or targets in amicroarray. The microarray can be used to monitor the expression levelof large numbers of genes simultaneously and to identify geneticvariants, mutations, and single nucleotide polymorphisms. Suchinformation may be used to determine gene function; to understand thegenetic basis of a condition, disease, or disorder; to diagnose acondition, disease, or disorder; and to develop and monitor theactivities of therapeutic agents. (See, for example, Brennan et al.(1995) U.S. Pat. No. 5,474,796; Schena et al. (1996) Proc. Natl. Acad.Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT applicationWO95/251116; Shalon et al. (1995) PCT application WO95/35505; Heller etal. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller et al. (1997)U.S. Pat. No. 5,605,662.)

Hybridization probes are also useful in mapping the naturally occurringgenomic sequence. The probes may be hybridized to: (a) a particularchromosome, (b) a specific region of a chromosome, or (c) artificialchromosome construction such as human artificial chromosome (HAC), yeastartificial chromosome (YAC), bacterial artificial chromosome (BAC),bacterial P1 construction, or single chromosome cDNA libraries.

Labeling of Molecules for Assay

A wide variety of labels and conjugation techniques are known by thoseskilled in the art and may be used in various nucleic acid, amino acid,and antibody assays. Synthesis of labeled molecules may be achievedusing Promega (Madison Wis.) or Amersham Pharmacia Biotech kits forincorporation of a labeled nucleotide such as ³²P-dCTP, Cy3-dCTP orCy5-dCTP or amino acid such as ³⁵S-methionine. Nucleotides and aminoacids may be directly labeled with a variety of substances includingfluorescent, chemiluminescent, or chromogenic agents, and the like, bychemical conjugation to amines, thiols and other groups present in themolecules using reagents such as BIODIPY or FITC (Molecular Probes,Eugene Oreg.).

Feedback Control of Single Tethered Polymers to Repeatedly ProbePolymer-binding Macromolecules

This section explains the basic mechanisms of Klenow Fragment (KF)polymerase and how dissociation of KF from its DNA template can bedetected by monitoring the pore current amplitude and event dwell times.Furthermore, the identity of the next base to be added by KF can befound through the presence of long dwell time events (such as, forexample, but not limited to >20 msec). The long dwell time events canthen be detected and reacted to using dynamic voltage control using afinite state machine (FSM).

It has been shown that KF bound to a DNA hairpin captured in a nanoporecan be differentiated from DNA hairpin alone based on current amplitude.Also, the identity the next base to be added the to a DNA hairpin can beidentified based on event dwell time. The ability to detect and react todifferent DNA/enzyme configurations and identify the base beingcatalyzed by KF is a strong motivator for the control of enzyme functionand development of a nanopore-based sequencing method, though furtherdetection and control precision is necessary.

The automated detection and control of single DNA hairpin moleculesusing the nanopore system is now described. Precise control of singleDNA molecules is necessary to make multiple sequential baseidentifications as would be employed in nanopore-based sequencing. DNAhairpin events are detected and it is shown that their dwell time can beregulated. The results presented demonstrate the level of controlnecessary for regulation of repeated enzyme binding events with a singlepiece of DNA captured in a nanopore.

It has been shown that individual DNA hairpins can be detected andcontrolled based on the amplitude of the Nanopore current signal. TheDNA hairpin's dwell time can be extended by reducing the applied voltageupon detection of a hairpin in the pore. Longer dwell times provide moresignal that can be used to identify the terminal base pair of thehairpin using machine learning methods (See for example, Vercoutere, etal. (2001) Nat. Biotechnol, 19(3): 248-252; and Akeson (2003) Nucleicacids research, 31: 1311-1318). An extension of the control demonstratedhere allows for the use of a single DNA hairpin to capture multipleenzymes, as shown below.

In Examples XX through XXXIX, the repeated capture of enzymes with asingle DNA hairpin is demonstrated. Multiple enzyme experiments can beperformed rapidly, offering higher throughput compared to atomic forcespectroscopy (AFM) and optical tweezer methods, which require manualattachment to the molecules to be measured (See Elio et al. (2005)Nature, 438(7067): 460-465; and Greenleaf and Block (2006) Science,313(5788): 801). The ability to rapidly probe DNA/enzyme interactionsprovides further motivation for nanopore-based sequencing.

Basic detection and control of a single DNA hairpin for repeated captureof KF has been demonstrated. Real time detection of enzyme dissociationcan be made by recognizing the terminal step present in the nanoporecurrent signal of binary and ternary complex translocation events.Repeatedly probing an enzyme using a single piece of DNA achieves themechanical action necessary for quick reading of long sequences of DNAusing a nanopore. More work needs to be done to regulate single baseadditions by KF, which is also necessary for sequencing using ananopore. The terminal step detection methods presented here offersatisfactory results, but fewer false detects are necessary forsequencing using enzyme fishing to be practical.

Improvements to the enzyme fishing mechanism have been proposed. Theexponentially weighted moving average filter replace the moving averagefilter used previously to reduce computational complexity and improvesignal smoothing. An enzyme dissociation check that can confirm fishingmay be performed with a bare DNA hairpin to ensure each detected enzymeevent is a new enzyme binding event. This is important for use ofstatistical models for sequencing because models assume new enzymebinding events. Higher signal-to-noise can be achieved through use of alonger DNA hairpins that would allow the use of higher control voltages.Reliable detection and reaction to DNA/enzyme unbinding will allow foraccurate base identification from repeated enzyme event data.

FIGS. 18 through 25 show how a blocking molecule, in this case ablocking oligonucleotide, can be used to limit enzyme activity to onemolecule or complex using a nanopore. Experimental details are morefully described in Examples XXXIV-XXXIX below.

In FIG. 18, DNA primer/template pairs are pre-annealed with afunctionalized blocking oligomer that inhibits strand displacement andreplication by A-family DNA polymerases (a). Upon nanopore capture (b),a non-complementary tail on the blocking oligomer allows the nanopore tounzip the block as the template is driven into the pore vestibule. Thenanopore acts as an electronic helicase. Once the blocking oligomer isremoved a finite state machine (FSM) commands a reduction of themembrane potential allowing a complementary oligomer to bind the DNAtemplate in the trans compartment (c) while the dsDNA/ssDNA junction isprotected from polymerases in the pore vestibule. Once tethered in thismanner, the DNA can be repeatedly ‘fished’ at defined intervals into thebuffer compartment containing enzymes and nucleotide triphosphate(dNTP/rNTP) substrates (d), and then probed for enzyme binding (e) orcatalysis under picoNewton forces (f). After one DNA template has beenexamined, it can be automatically ejected (f)-(g), and another templatecaptured in rapid succession.

FIG. 19 illustrates exemplary blocking oligomer structures that may beused to inhibit bulk phase DNA synthesis. FIG. 19(a) represents a DNApolymerase substrate consisting of a 79 mer template strand (tan andblack) and a 23 mer primer strand (dark blue). In (b), thesingle-stranded region of the template beyond the 3″end of the primerstrand is magnified. This region is the target for a series ofoligonucleotides (c)-(g) intended to inhibit DNA synthesis in the bulkphase bathing the nanopore. These blocking structures are (c), astandard DNA oligonucleotide (red) complementary to 25 templatenucleotides; (d), the oligonucleotide shown in (c), extended on its3″end by 7 non-complementary cytosine residues; (e), the oligonucleotideshown in (d), with a single acridine residue at its 5″terminus; (f), theoligonucleotide shown in (d), with two acridine residues at its 5′terminus; and (g), a pyrimidine:purine-purine triple helix. Thepurine-rich third strand of the triple helix is shown in light blue. Inpanels (e) and (f), acridine residues are depicted as yellow rectanglesintercalated into the DNA helix. Two versions of the oligonucleotideshown in e can be used; in one (referred to as “e.i” in the caption forFIG. 20), acridine replaced the 5″base in the sequence of (d), in theother (referred to as “e.ii” in the caption for FIG. 20), the 5′ base ispresent and acridine is incorporated as a 5′ extension. For theoligonucleotide in (f), acridine is incorporated at both of thesepositions. n=0 is the position at which a DNA polymerase would add thefirst incoming nucleotide during replication.

FIG. 22 shows a key finding that the long, higher amplitude currentsegments characteristic of polymerase binding without blocking oligomer(I_(EBS) in FIG. 21, see plot of current and 2-D plot) are absent in thepresence of the blocking oligomer. A 2-D plot of dwell time vs.amplitude of hundreds of similar events is also included in FIG. 21. Thenear complete absence of events with EBS amplitudes is consistent withthe near complete inhibition of primer extension observed by gelelectrophoresis (FIG. 20). Similar experiments may be used to validatethe efficacy of more advanced blocking oligomers (FIG. 19) forprevention of ternary complex formation in bulk phase.

We have demonstrated control of DNA displacement at single nucleotideprecision on the nanopore FIG. 25. That is, combining active control andthe blocking oligomer strategy we showed that T7 DNA polymerase can beused to translocate ssDNA in a biopore. This real time experimentdocumented enzymatic displacement of three nucleotides under a 90 mVresistive load, and therefore establishes polymerase regulation of DNAin the nanopore.

Diagnostics

The polynucleotides, fragments, oligonucleotides, complementary RNA andDNA molecules, and PNAs may be used to detect and quantify altered geneexpression, absence/presence versus excess, expression of mRNAs or tomonitor mRNA levels during therapeutic intervention. Conditions,diseases or disorders associated with altered expression includeidiopathic pulmonary arterial hypertension, secondary pulmonaryhypertension, a cell proliferative disorder, particularly anaplasticoligodendroglioma, astrocytoma, oligoastrocytoma, glioblastoma,meningioma, ganglioneuroma, neuronal neoplasm, multiple sclerosis,Huntington's disease, breast adenocarcinoma, prostate adenocarcinoma,stomach adenocarcinoma, metastasizing neuroendocrine carcinoma,nonproliferative fibrocystic and proliferative fibrocystic breastdisease, gallbladder cholecystitis and cholelithiasis, osteoarthritis,and rheumatoid arthritis; acquired immunodeficiency syndrome (AIDS),Addison's disease, adult respiratory distress syndrome, allergies,ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis,autoimmune hemolytic anemia, autoimmune thyroiditis, benign prostatichyperplasia, bronchitis, Chediak-Higashi syndrome, cholecystitis,Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus,emphysema, erythroblastosis fetalis, erythema nodosum, atrophicgastritis, glomerulonephritis, Goodpasture's syndrome, gout, chronicgranulomatous diseases, Graves' disease, Hashimoto's thyroiditis,hypereosinophilia, irritable bowel syndrome, multiple sclerosis,myasthenia gravis, myocardial or pericardial inflammation,osteoarthritis, osteoporosis, pancreatitis, polycystic ovary syndrome,polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis,scleroderma, severe combined immunodeficiency disease (SCID), Sjogren'ssyndrome, systemic anaphylaxis, systemic lupus erythematosus, systemicsclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Wernersyndrome, hemodialysis, extracorporeal circulation, viral, bacterial,fungal, parasitic, protozoal, and helminthic infection; a disorder ofprolactin production, infertility, including tubal disease, ovulatorydefects, and endometriosis, a disruption of the estrous cycle, adisruption of the menstrual cycle, polycystic ovary syndrome, ovarianhyperstimulation syndrome, an endometrial or ovarian tumor, a uterinefibroid, autoimmune disorders, an ectopic pregnancy, and teratogenesis;cancer of the breast, fibrocystic breast disease, and galactorrhea; adisruption of spermatogenesis, abnormal sperm physiology, benignprostatic hyperplasia, prostatitis, Peyronie's disease, impotence,gynecomastia; actinic keratosis, arteriosclerosis, bursitis, cirrhosis,hepatitis, mixed connective tissue disease (MCTD), myelofibrosis,paroxysmal nocturnal hemoglobinuria, polycythemia vera, primarythrombocythemia, complications of cancer, cancers includingadenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma,teratocarcinoma, and, in particular, cancers of the adrenal gland,bladder, bone, bone marrow, brain, breast, cervix, gall bladder,ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle,ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin,spleen, testis, thymus, thyroid, and uterus. In another aspect, thepolynucleotide of the invention.

The polynucleotides, fragments, oligonucleotides, complementary RNA andDNA molecules, and PNAs, or fragments thereof, may be used to detect andquantify altered gene expression; absence, presence, or excessexpression of mRNAs; or to monitor mRNA levels during therapeuticintervention. Disorders associated with altered expression includeakathesia, Alzheimer's disease, amnesia, amyotrophic lateral sclerosis,ataxias, bipolar disorder, catatonia, cerebral palsy, cerebrovasculardisease Creutzfeldt-Jakob disease, dementia, depression, Down'ssyndrome, tardive dyskinesia, dystonias, epilepsy, Huntington's disease,multiple sclerosis, muscular dystrophy, neuralgias, neurofibromatosis,neuropathies, Parkinson's disease, Pick's disease, retinitis pigmentosa,schizophrenia, seasonal affective disorder, senile dementia, stroke,Tourette's syndrome and cancers including adenocarcinomas, melanomas,and teratocarcinomas, particularly of the brain. These cDNAs can also beutilized as markers of treatment efficacy against the diseases notedabove and other brain disorders, conditions, and diseases over a periodranging from several days to months. The diagnostic assay may usehybridization or amplification technology to compare gene expression ina biological sample from a patient to standard samples in order todetect altered gene expression. Qualitative or quantitative methods forthis comparison are well known in the art.

The diagnostic assay may use hybridization or amplification technologyto compare gene expression in a biological sample from a patient tostandard samples in order to detect altered gene expression. Qualitativeor quantitative methods for this comparison are well known in the art.

For example, the polynucleotide or probe may be labeled by standardmethods and added to a biological sample from a patient under conditionsfor the formation of hybridization complexes. After an incubationperiod, the sample is washed and the amount of label (or signal)associated with hybridization complexes, is quantified and compared witha standard value. If the amount of label in the patient sample issignificantly altered in comparison to the standard value, then thepresence of the associated condition, disease or disorder is indicated.

In order to provide a basis for the diagnosis of a condition, disease ordisorder associated with gene expression, a normal or standardexpression profile is established. This may be accomplished by combininga biological sample taken from normal subjects, either animal or human,with a probe under conditions for hybridization or amplification.Standard hybridization may be quantified by comparing the valuesobtained using normal subjects with values from an experiment in which aknown amount of a substantially purified target sequence is used.Standard values obtained in this manner may be compared with valuesobtained from samples from patients who are symptomatic for a particularcondition, disease, or disorder. Deviation from standard values towardthose associated with a particular condition is used to diagnose thatcondition.

Such assays may also be used to evaluate the efficacy of a particulartherapeutic treatment regimen in animal studies and in clinical trial orto monitor the treatment of an individual patient. Once the presence ofa condition is established and a treatment protocol is initiated,diagnostic assays may be repeated on a regular basis to determine if thelevel of expression in the patient begins to approximate the level thatis observed in a normal subject. The results obtained from successiveassays may be used to show the efficacy of treatment over a periodranging from several days to months.

Purification of Ligand

The polynucleotide or a fragment thereof may be used to purify a ligandfrom a sample. A method for using a polynucleotide or a fragment thereofto purify a ligand would involve combining the polynucleotide or afragment thereof with a sample under conditions to allow specificbinding, detecting specific binding, recovering the bound protein, andusing an appropriate agent to separate the polynucleotide from thepurified ligand.

In additional embodiments, the polynucleotides may be used in anymolecular biology techniques that have yet to be developed, provided thenew techniques rely on properties of polynucleotides that are currentlyknown, including, but not limited to, such properties as the tripletgenetic code and specific base pair interactions.

To our knowledge, we are the first investigators to use an FPGA tocontrol and measure complexes in a nanopore. (See Hornblower et al.(2007) Nature Meth. 4: 315-317.) We believe that similar functionalitycould be achieved with an appropriate microprocessor. FSM logic has beenused as part of a machine learning approach used to identify theterminal base pair of the blunt end of DNA hairpins (see Vercoutere, etal. (2001) Nat. Biotechnol, 19(3): 248-252; Winters-Hilt et al. (2003)Biophys. J., 84(2): 967-976). This is a much different application of anFSM in which its primary role was for training the machine learningmodels offline; our FSM functionality is used for online voltagecontrol.

Direct control of ssDNA in a nanopore (no enzymes) has been demonstrated(Bates et al (2003) Biophysical Journal, 84: 2366-2372) in whichdetection of DNA is based on monitoring the raw amplitude relative to athreshold level. Voltage level changes, comparable to those employed inWilson et al. ((2008) ibid), were commanded to explore the zero and lowvoltage effects on ssDNA-pore interactions. In contrast to thresholdingthe raw ionic current amplitude, our approach filters the current inreal time (details given in the Examples).

Alternative methods for single-molecule sensing and manipulation includeoptical tweezers and atomic force microscopy (see Bustamante et al.(2003) Nature, 421: 423-427). For example, optical trapping has beenused to sequence DNA by attaching a processive enzyme to a polystyrenebead (see Abbondanzieri et al (2005) Nature, 438(24):460-465; andGreenleaf and Block (2006) Science, 313:801). At present, greaterspatial and temporal resolution of single DNA molecule polymerizationhas been achieved than with nanopores. However, these methods generallyrequire more preparative steps, and far fewer molecules can be analyzedover a common time period.

Our invention uses feedback control of a single tethered DNA moleculesuspended in a nanopore for repeated capture and subsequent dissociationof individual DNA-binding enzymes. There are two phases to ourimplementation.

First, a single DNA molecule with single and double stranded segments iscaptured, by the single-stranded end, and then tethered, by making thesingle-stranded segment double-stranded on the trans side. In thisconfiguration, with double-stranded segments on both cis and trans sidesof the channel, the DNA will remain in the channel until a sufficientvoltage force unzips the double-stranded segments from the cis or transside. The length of the single-stranded segment in the channel is chosensuch that, under negative voltages, exposure of the single-to-doublestranded (ss-ds) junction in the cis chamber is sufficiently availablefor KF binding.

In the second phase, the tethered DNA is used for repeated capture anddissociation of KF enzymes in the cis chamber of the nanopore. Byanalogy with fishing, the DNA is the line and bait (with the ss-dsjunction as the hook), and the enzymes are the fish (which can be caughtonly one at a time). Details are now given on our setup, control logic,related approaches in the literature, and our initial demonstration ofrepeated KF binding to a tethered DNA molecule in a nanopore.

Impact and Refinement of Tethered DNA Capability

For the purpose of exploring the interaction of enzymes that bind ormodify DNA or RNA (exonucleases, kinases, and other polymerases), withDNA or RNA captured in a nanopore, we consider that the inventiondisclosed herein will have the following technological impacts:

Substantial Increase in Data Throughput.

-   -   In the tethered configuration, a negative voltage is used in        fishing mode, and a positive voltage is used for probing mode.        In probing mode, all information contained in the ionic current        can be used for characterization of the polymer alone or        polymer-enzyme interactions, at any desired probing voltage. In        non-tethered configuration, independent events (including        capture, blockage of nanopore, and eventual translocation of        polymer) contain the information relevant for analysis of        polymer alone or polymer-enzyme interactions. A sufficient        voltage is required for capture of each molecule, the time        between events is not controllable, and lower capture voltages        increase the time between events. Thus, the tethered        configuration increases the throughput of analyzable data, by        increasing the number of analyzable events over a common period        and by increasing the range of probing voltages.

Reduction in Non-Analyzable Data.

In probing mode, the ionic current contains information about thetethered polymer alone or the interaction of an enzyme bound to thetethered polymer. In non-tethered configuration, up to 50% of eventsrecorded within an experiment can be unrelated to the kinetics ofinterest. For example, brief blockades caused by the ds-end of a DNAhairpin contacting the cis-side of the pore would be included in data inthe non-tethered configuration, but not in the tethered configuration.

Substantial Increase in Sensitivity of Nanopore Sensor for Real-TimeDetection of the Addition of Biological Components in Cis Chamber.

Post-experiment analysis demonstrates the sensitivity of nanoporesensors for detection of the presence of Mg²⁺ cofactor and complementarydNTP of KF. In both cases, detection is based on the increase in dwelltime for the KF-bound portion of binary/ternary events. By monitoringthe dwell time of KF-bound portions of events in real time, the tetheredconfiguration offers a new capability for online detection of additionof Mg²⁺ and complementary dNTP components to the cis-chamber. The samecapability can be utilized with other enzymes and their correspondingevent-sensitive components. In our future tethered DNA experiments withKF, real-time detection capabilities will be explored as a function offishing time, dNTP concentration, Mg²⁺ concentration, and probingvoltage.

Screening of Drug Candidates

Another aspect of the invention is to use the methods disclosed hereinto analyse and detect binding of an activated DNA-binding molecule, forexample, a transcriptional regulator such as a transcription factor, anucleotide polymerase, an transcriptional enhancer, and a regulatorypolynucleotide, or the like, that will only bind the DNA in the presenceof a ligand. In one typical example, the ligand is a drug candidate andthe DNA-binding molecule is a transcription factor that is activated byan endogenous ligand. In another alternative, the DNA-binding moleculewill only bind the DNA in the absence of a ligand. Such ligands havingeither activity or both activities are well known in the art and aredisclosed herein. For example, typical ligands such as, but not limitedto, retinoic acid, thyroid hormone (for example, T3 and T4), steroidhormones such as androgens, estrogens, progesterones, cortisols, and thelike, peroxisome-proliferators, isoprenoid alcohols (for example,farnesol), as well as products of intermediary metabolism, such as, butnot limited to, sugars and their derivatives, lipids and theirderivatives, nucleotiside co-factors and the like, and nucleic acids,such as, but not limited to, miRNAs, asRNAs, and products ofpseudogenes, may be the endogenous (naturally-occurring) ligand. It isdesirable and one of the considerations of the invention, that candidatesynthetic drugs that have homologies, structural, chemical, and/orspatial, may be identified using the methods disclosed herein and may beused in various therapies for diseases and disorders, for example,neurological disorders, reproductive disorders, disorders of metabolism,metaplasia, such as cancer, and inflammatory disorders.

The methods disclosed herein can provide for high-throughput screeningof such candidate drugs at low cost and having a high rate of confidencein any data so derived.

The invention will be more readily understood by reference to thefollowing examples, which are included merely for purposes ofillustration of certain aspects and embodiments of the present inventionand not as limitations.

EXAMPLES

Herein are described several examples to demonstrate the capability ofmeasuring macromolecules and polanions or polycations.

Example I Enzyme Binding is Prevented by a Blocking Oligomer

For an illustration of this method, see FIGS. 1(a) through 1(g). (a) Inthis scenario, the blocking oligomer is bound to the primer/template inbulk phase. Structure of the ternary complex prevents binding of theenzyme to the junction between the dsDNA and ssDNA segments of thetarget DNA where the first nucleotide would be incorporated. (b) Captureof a blocked primer/template under an applied voltage (trans sidepositive) threads the ssDNA into the pore and perches the dsDNA abovethe vestibule. This occurs because the loop at the end of the blockingoligomer is too large to enter the vestibule. The current reportscapture of the complex in this state. (c) Under the applied voltage, thessDNA segment advances in the pore toward the trans-side andprocessively unzips base-pairs between the blocking oligomer and thetemplate. The energy cost of releasing each base pair independently issmall (about 2.5 kcal/mol), so it proceeds rapidly under force. Duringthis unzipping process the current is the same as in (b) because thedsDNA segment cannot enter the vestibule. (d) Release of the blockingoligomer following unzipping. Absent the blocking oligomer, the dsDNAsegment of the target DNA can enter the pore vestibule. This results ina measurable reduction in current that signals release of the blockingoligomer and activation of the target DNA. (e) Voltage reversal exposesthe activated dsDNA/ssDNA junction for enzyme binding. By reversingvoltage, the negatively charged DNA is driven back into the ciscompartment. (f) Absent the blocking oligomer, enzymes can bind to theDNA at the targeted position (the dsDNA/ssDNA junction in this example).(g) Probing for bound enzyme or DNA modification. Following a definedamount of time (typically hundreds of microseconds to seconds), thevoltage can be reversed once again to its original polarity, thuspulling the DNA back into the nanopore. Current readout can be used todetermine if an enzyme has been bound (shown) or if the DNA duplexterminus has been modified (not shown). If the result is negative, steps(e)-(g) can be repeated.

Example II Enzyme Catalysis is Prevented by a Blocking Oligomer

For an illustration of this method, see FIGS. 2(a) through 2(g). (a) Inthis scenario, the blocking oligomer is bound to the primer/template inbulk phase. Structure of the ternary complex permits binding of theenzyme to the target DNA but catalysis and processing along the templateare prevented. (b) Capture of a blocked primer/template under an appliedvoltage (trans-side positive) threads the ssDNA into the pore andperches the dsDNA above the vestibule. This occurs because the loop atthe end of the blocking oligomer is too large to enter the vestibule.The current reports capture of the complex in this state. (c) Under theapplied voltage, the ssDNA segment advances in the pore toward thetrans-side and processively unzips base-pairs between the blockingoligomer and the template. The energy cost of releasing each base pairindependently is small (about 2.5 kcal/mol), so it proceeds rapidlyunder force. During this unzipping process the current is the same as in(b) because the dsDNA segment cannot enter the vestibule. (d) Release ofthe blocking oligomer following unzipping results in activation of thecomplex. Unlike the scenario disclosed in FIG. 1, the dsDNA segment ofthe target DNA cannot enter the pore vestibule when the blockdissociates because the bound enzyme is too large to enter. Thus theaverage current does not change. (e) Reducing the applied voltagepermits the enzyme to proceed. There remains sufficient ionic currentfor analysis. (f) The template strand is copied to completion. (g) Thecomplex dissociates and the nanopore is now ready to capture andactivate another DNA target (see step a).

Example III Enzyme Catalysis is Activated by Injection of Mg²⁺ Across aNanopore

For an illustration of this method, see FIGS. 3(a) through 3(c). (a) Inthis example scenario, the cis compartment contains all componentsnecessary for DNA polymerase activity except for Mg²⁺. Thus, nocatalysis can take place. (b) When voltage is applied (trans-side +),Mg²⁺ is driven across the pore into the cis compartment. (c) When aDNA-polymerase complex is captured by the pore, the Mg²⁺ concentrationin the volume immediately adjacent to the pore is sufficiently high topermit Mg²⁺ occupation of the two critical loci in the enzyme'scatalytic site. Polymerization of the copied strand can then occur.Ternary complexes in the bulk phase cannot catalyze DNA synthesisbecause the Mg²⁺ concentration distal from the pore is essentially zero.This scenario could be applied to other substances that are required forDNA synthesis and that are small enough to permeate the nanopore undercontrolled conditions.

Example IV Measuring Polymerase Activity Using a Biological Nanopore,α-Hemolysin

The polymerase activity of DNA polymerase I is largely contained in asmaller structure called the Klenow fragment. In this application, theKlenow fragment is allowed to bind to a strand of DNA (the template)that has undergone complementary base pairing with an oligomer ofdefined base sequence. The protein is drawn to the pore and the ioniccurrent through the pore is thereby reduced. Two different enzymaticfunctions can be monitored. 1) When the protein is released from itsbinding site on the primer-template complex, a characteristic transientreduction of ionic current is produced. 2) When the enzyme is suppliedby the appropriate dNTP substrate, a characteristic lengthening of theresidence time of the enzyme in the pore is produced. Incorrect dNTPsubstrates do not alter the residence time.

Example V Detecting Ligand Binding to a Receptor Protein

The cytoplasmic estradiol receptor is covalently linked to a 100mer ofpolyaspartic acid by formation of an appropriate covalent bond, such asthat produced by a cross-linking agent. The receptor is positioned at a3 nm diameter silicon nitride pore by the electric field acting on thepolyaspartic acid in its anionic form. The pore has a monolayer of abifunctional alkyl sulfide attached to a gold layer on the pore. Afterpositioning, the receptor is covalently bonded to the pore by formationof disulfide bonds between the alkyl groups on the pore and cysteinegroups on the receptor. When estradiol is present, it binds to the highaffinity site on the receptor and alters ionic current though the pore,thereby providing a means of detecting this steroid hormone withsingle-molecule sensitivity.

Example VI Detecting Glucose Oxidase Activity

Following the procedure outlined in Example V, a glucose oxidasemolecule is attached to a silicon nitride pore. When glucose is present,the enzymatic action produces detectable transient changes in the ioniccurrent through the pore as the glucose binds to the active site,oxidation, and release of products.

Example VII Monitoring Ribosome Function

A ribosome preparation is exposed to a specific mRNA in the presence ofa commonly used translation system such as cytosolic extract of E. coli.The system is maintained near 0° C. in order to inhibit ribosomefunction. Alternatively ribosomes may be inactivated by excluding arequired cofactor such as an elongation factor or tRNAs. When a singleribosome attaches to the mRNA, it can be positioned at the pore bydrawing the mRNA through the pore by the action of a transmembranevoltage of 100 mV or more. The mixture is then rapidly warmed to 25° C.to initiate protein synthesis or addition of a required cofactor. Theindividual steps of protein synthesis are then monitored by the combinedeffects on ionic current that are produced by mRNA being drawn throughthe pore by the ribosome action, and cyclic conformational changes ofthe ribosome as it proceeds through the steps of translation.

Example VIII Feedback Control of a Single Tethered DNA MoleculeSuspended in a Nanopore to Repeatedly Probe DNA-Binding Enzymes

In the biological nanopore setup, a planar lipid bilayer is createdacross a 50-100 μm TEFLON aperture in a KCl solution, and a singleα-hemolysin protein channel self-inserts into the planar lipid. Thechannel (pore) is 15 nm in length and varies in diameter. Thecis-opening of the pore is 2.6 nm wide, opening to a 3.6 nm vestibulebefore narrowing to a limiting 1.5 nm width at the beginning of thestem. The remainder of the stem up to the trans-opening is 2 nm wide.The vestibule is large enough for double-stranded DNA (dsDNA) to enter,but the limiting stem is just wide enough for single-stranded DNA(ssDNA) to pass through. AgCl electrodes are used to apply a potentialacross the bilayer that produces an ionic current through the pore (FIG.7). The field created by this voltage pulls the negatively chargedphosphate backbone of the ssDNA or RNA through the pore, passing fromthe cis side to the trans side of the pore with the trans-side voltagepositive. As molecules translocate, the pore becomes partially blockedby the translocating molecule, causing a drop in current. Thesetranslocation events can be characterized by the amplitude of theattenuated (blockade) current and the time the molecule spends in thepore, defined as the dwell time. A schematic of the nanopore system andan example DNA translocation event is shown in FIG. 8. The DNA shown inFIG. 8 has single and double-stranded segments, with the double-strandedsegment as a 20 base pair hairpin (20 bphp). The DNA is captured by thesingle-stranded end into the nanopore, and translocates once the voltagefield force causes the hairpin to unzip within the vestibule. Thisconfiguration has utility towards a part of the instant invention. Theutility of the double-stranded segment is that it extends the dwell time(by stopping translocation) of the DNA, briefly, until the voltageshears the segment into single stranded DNA and the DNA translocates.Additionally, longer double-stranded segments yield longer dwell timesat a given voltage. In contrast, for ssDNA or RNA, translocation ratesreach up to 2 nucleotides/μsec with no pauses in translocation undercapture-level voltages.

We note that the double-stranded segment may alternatively be formed byannealing a primer DNA segment, with the complementary bases, to the endof single-stranded DNA. The key is that, in our configuration, thecaptured DNA molecule must have single and double-stranded segments.This structure facilitates capture and retention: the single-strandedend is captured, and the double-stranded end increases the dwell time,providing time to detect capture and react by reducing the voltage to ahold level (explained in more detail below). Another key reason forusing this DNA structure is that the enzyme exploited in our proposedapproach binds to the DNA precisely at the single-to-double strandedjunction of the DNA.

Example IX Nanopores and Enzymes

We have used biological nanopores to probe the interaction of enzymewith a captured DNA molecule. Under an applied voltage, the ssDNA end ofenzyme-bound DNA is captured in the nanopore, with the enzyme residingon top of the nanopore being too large to translocate through it.Kinetics of Escherichia coli exonuclease I (ExoI) binding to ssDNA hasbeen quantified using voltage ramps for nanopore-based forcespectroscopy. Specifically, upon detection of capture of ssDNA, voltageis automated to briefly hold the ssDNA-ExoI complex, then implement avoltage ramp until ExoI dissociates and the ssDNA translocates throughthe pore. The time-to-dissociation under the applied voltage ramp is inturn used to estimate binding rate constants.

Previously (see Benner, et al. (2007) Nature Nanotechnology, 2: 718-724)we have explored the interaction of DNA with the Klenow fragment (KF) ofEscherichia coli DNA polymerase I. In the absence of KF, capture andsubsequent unzipping of 14 bphp at constant 180 mV reveals blockadeswith 20 pA mean amplitude and 1 msec median dwell time (FIG. 9a ).Addition of 2 μM KF yielded a new population of events attributable tobinary complexes (DNA/KF) with higher mean amplitude (23 pA), andresulted in an event plot (FIG. 9b II) with a longer dwell time (3 msecmedian of all events). Addition of 200 μM deoxyguanosine triphosphate(dGTP), the dNTP complementary to the DNA template base in the KFcatalytic site, extended the dwell time of the new population to 133msec median, attributable to a higher stability bond within ternarycomplexes (DNA/KF/dGTP).

Our tethered DNA configuration described in the next section leverages asignificant structural feature exhibited by KF-bound DNA events (with orwithout the complementary dNTP, that is, binary or ternary complexes),now described. Closer investigation of the binary and ternary complexblockades revealed a two-step pattern in greater than 90% and 97% of theblockades, respectively. The first step has a 23 pA mean amplitude,followed by a brief (1 msec median dwell time) second step, referred toas the terminal step at 20 pA mean amplitude. It was demonstrated thatthe transition from step one to step two resulted in dissociation of KF(for binary and ternary complexes) from DNA, followed by hairpindropping into the pore vestibule until translocation occurred. Thus, theterminal step kinetics are precisely the DNA duplex unzipping kinetics.

The consistent presence of the terminal step within enzyme-bound DNAevents is mechanistically of importance to our invention. In particular,for an enzyme-bound DNA complex captured in the nanopore under aconstant voltage, the terminal step makes it possible to detect inreal-time that enzyme has dissociated from the DNA, on the basis of thechange in amplitude (from 23 pA to 20 pA at 180 mV in our recent workwith KF).

Example X Detection and Control of DNA and KF-Bound DNA in a Nanopore

In this approach, the voltage control logic is programmed using a finitestate machine (FSM) within the LabVIEW 8 software, and the FSM logic isimplemented on a field-programmable gate array (FPGA) hardware system.Our first implementation of FSM/FPGA voltage control demonstratedefficient automated detection of individual ternary complexes, based onthe characteristic 23 pA amplitude and a dwell time of at least 20 msec.For all events that remained within the threshold range of 21.2-26.8 pAfor 20 ms, the voltage was reversed to expel the complex back into thecis chamber, rather than waiting (>100 msec median dwell time) fordissociation of enzyme and DNA translocation to the trans side. Thecontrol logic had the effect of concentrating the dwell time of thedetected ternary complex events, from a median dwell time of 123 msec(235 msec interquartile range (IQR)) without FSM/FPGA control, to amedian dwell time of 23 msec (0.3 msec IQR) with FSM/FPGA control. Sinceless than 2% of DNA and binary events were longer than 20 msec, thewaiting period of 20 msec ensured that nearly all controlled events wereternary complexes.

In our second implementation of FSM/FPGA voltage control, wedemonstrated efficient automated detection of individual DNA complexes(no KF enzyme present in cis-chamber), based on the characteristic 20 pAamplitude (Wilson et al. (2008) Rapid finite state machine control ofindividual DNA molecules in a nanopore. In International Conference onBiomedical Electronics and Devices (BIODEVICES), to appear, Madeira,Portugal). For all events that fell within a threshold range of 20+2.8pA, the voltage was promptly reduced to extend the DNA dwell time. In asecond experiment, for all DNA events that fell within a thresholdaround the 20 pA level, the voltage was promptly reversed to expel theDNA back into the cis chamber prior to translocation. Bothimplementations (detecting and reacting to enzyme-bound DNA events anddetecting and reacting to enzyme-free DNA events) were foundationalachievements, and prompted us to attempt to detect and discern betweenboth types of events individually, and in real time.

Example XI Equipment

A patch-clamp amplifier, Molecular Devices AxoPatch 200B, regulates theapplied voltage and measures the ionic current through the channel. Thedata are recorded using the Molecular Devices Digidata 1440A digitizer,sampled at 50 kHz and low-pass filtered at 5 kHz with a four-pole Besselfilter. One of our stations uses a different patch clamp, the A-MSystems Model 2400.

Example XII Control Logic: Hardware and Software

The voltage control logic is programmed using a finite state machine(FSM) within the LabVIEW 8 software. The FSM logic is implemented on afield-programmable gate array (FPGA) hardware system, NationalInstruments PCI-7831R. An FPGA is a reconfigurable hardware platformthat permits fast measurement and voltage reaction times (1 μsec outputsample time). An FSM is a logic construct in which program execution isbroken up into a series of individual states. Each state has a commandassociated with it, and transitions between states are a function ofsystem measurements. Measurements of the pore current are processed andpassed to the FSM as inputs. Changes in the FSM control logic are madeas necessary, without the need to re-compile and re-route the design torun on the FPGA. This achieves a balance between speed and flexibility,by enabling the system to react to events on the order of a microsecond,while also allowing for the control logic to be reconfigured asnecessary between experiments.

Example XIII Filtering and Thresholding Ionic Current

Our control logic requires efficient detection of ionic currentblockades (events) that result from DNA alone or KF-bound DNA. Further,the logic must be able to efficiently distinguish between these twoevent types. At 180 mV, mean amplitudes for DNA alone and KF-bound DNAare 20 pA and 23 pA, respectively; a difference of 3 pA. To distinguishDNA alone from KF-bound DNA events in real time, the incoming currentsignal on the FPGA is filtered and thresholded.

Threshold levels are determined a priori, by constant voltageexperiments with the biological components to be detected in the cischamber. In our experiments with KF, amplitude thresholds consistentwith KF-bound or KF-free event amplitudes were identified at 180 mV and150 mV. At 180 mV, for example, the threshold identified and used todetect DNA alone events was 20±2.8 pA; the threshold identified and usedto detect KF-bound DNA events in was 24±2.8 pA. In our experiments todate, one or two thresholds have been implemented at a time. In futurework, more than two thresholds may be utilized at the same time, todistinguish multiple macromolecular states that are known to differbased on the attenuated amplitude.

Filtering is used to mitigate noise. Since the ionic currentpeak-to-peak noise routinely exceeds 3 pA at 180 mV, DNA alone andKF-bound DNA events would not be reliably distinguishable by monitoringthe raw current amplitude. By filtering the current amplitude, we havedemonstrated detection of DNA alone events and KF-bound DNA events inreal time. A windowed mean filter has been used in our experiments sofar, including in our initial demonstration shown in the Examples above.Recently, a superior exponentially-weighted mean filter was identifiedand will be used in new experiments. Details on the two filters aregiven below.

Example XIV Moving Average Filter

Every 5.3 sec, the FPGA samples the ionic current and computes awindowed mean amplitude, using a window size of 0.75 msec. If the meanenters a chosen threshold range, the FPGA detects entry and continues tomonitor the mean, re-checking the threshold every 0.2 msec. If the meanremains within the threshold range for four consecutive checks, the FSMlogic diagnoses the blockade as an event type known to be consistentwith the chosen threshold.

In the absence of a change in voltage, the expected time delay betweenthe start of an event and diagnosis of an event is 1.35 msec; 0.75 msecfor the windowed mean to first enter the threshold, and 0.6 msec forthree more confirmed tests. In practice, the diagnosis time ranges from1.1 to 2.5 msec. The mean filter was implemented in our invention'sinitial demonstration (detailed below).

Example XV Exponentially-Weighted Moving Average Filter

Through post-experiment analysis, our mean filter was shown to falselydetect terminal steps within ternary events. Specifically, the FSM/FPGAwas programmed to detect ternary level amplitudes, wait until theterminal step, and upon detection of the terminal step, reverse thevoltage to expel the unbound DNA into the cis chamber. Examination ofthe data showed voltage reversal for many events in which no terminalstep was clearly present, although the presence of terminal steps internary events is high (97%) with no voltage reversal.

To improve the FSM's robustness to false detections of terminal steps,an exponentially-weighted moving average (EWMA) filter is now beingexplored to replace the mean filter. The EWMA filter represents adigital implementation of an analog RC filter commonly used for signalsmoothing in electrical engineering applications. The filter calculatesa moving average that places exponentially less significance on pastsamples and allows the filtered signal to better track the real signal.EWMA filtering also performs signal smoothing more efficiently than asimple moving average due to its recursive implementation:ī(t)=(1−α)i(t)+αī(t−1),  (1)

-   -   where i and ī are unfiltered and filtered current signals,        respectively, and t is the sample number. Filtering the data        from the terminal step detection experiments offline, with        α=0.9, showed a substantial improvement in robustness to false        positives over the mean filter. As with the mean filter, four        consecutive threshold tests will be used for event diagnosis,        waiting 0.2 msec between threshold tests.

In the absence of a change in voltage, the expected time delay betweenthe start of an event and diagnosis of an event is 0.7 msec; 0.1 msecfor the EWMA to first enter the threshold, and 0.6 msec for three moreconfirmed tests. More rigorous evaluation of EWMA detection times willbe part of our ongoing work.

Example XVI Time Scales for Changing the Voltage Field Force

When the magnitude of the voltage across the membrane changes, acapacitive transient is superimposed on the measured ionic current. Thetransient is present in all alpha-hemolysin nanopore studies thatinvolve voltage change (see, for example, Bates et al. (2003) supra),and necessarily masks some information in the measured current for adefined and manageable segment of each event. In our invention, thetransient implies that, when the control logic is programmed to diagnosean event type after a voltage change, the filtered current amplitudewill not enter a chosen threshold(s) for event diagnosis until thetransient has sufficiently settled.

The settling time for the transient is proportional to the net change involtage. In the voltage control experiment, the changes in appliedvoltage are from 180 mV to −50 mV, and −50 mV to 180 mV. For a netchange of 230 mV (absolute value), we observe that 98% of transientshave sufficiently decayed for accurate thresholding after 2.5 msec. Inour initial tethered DNA experiments, voltages changes were 200 mV and170 mV (absolute value). Transients resulting from voltage changes areobservable in FIGS. 12-13.

In the presence of a change in voltage, the time required for diagnosisof an event (as a DNA event or an enzyme-bound DNA event) is expected tomatch the voltage transient settling time. This is because the transientsettling time is typically longer than the time required for thefiltered amplitude to converge onto the measured ionic current signal.Thus, diagnosis time is expected to be at most 2.5 msec for voltagechanges of 230 mV (absolute value), and less than 2.5 msec for smallervoltage changes.

Example XVII Tethered DNA Configuration

In our initial tethered DNA experiments, a single DNA 20 bphp wascaptured in the pore, tethered, and threaded back and forth through thepore under voltage control for repeated KF binding and unbinding to thess-ds junction in the cis chamber. In the experiment, 1 μM 100mer DNA, 5mM MgCl₂, 2 μM KF, and 200 μM of dGTP were present in the cis well ofthe pore. Thus, each event results from DNA alone or a ternary complexcaptured in the nanopore.

The DNA oligomer is designed for tethering. Specifically, the 3′ end isformed into a 20 base pair hairpin, and 2 μM of 20mer primercomplementary to the 5′ end is present in the trans chamber. Uponcapture of the 5′ end, voltage is reduced to hold the DNA in the pore,but not unzip the 3′-end hairpin in the vestibule (if an unbound DNAmolecule was captured) or dissociate KF/dGTP from the ss-ds junction (ifa ternary complex was captured). After a sufficient time period, the20mer primer anneals to the 5′ end, creating a 20mer duplex on the transside of the pore. Details of our experiments are provided.

In the experiment, 180 mV applied voltage was used to capture each DNAmolecule in the pore with the 5′ end translocating into the transchamber. When a DNA event (threshold of [15.75, 21.25] pA) or a KF-boundDNA event (threshold of [21.25, 26.75] pA) was diagnosed using the meanfilter, the FSM reduced the potential to 50 mV, to hold the molecule inthe pore but not unzip the hairpin or dissociate KF/dGTP. The 50 mV holdvoltage was applied for 20 sec, a period sufficient for the 20mer primerto anneal to the 5′ end of the DNA in the trans chamber. The initialtethering phase of a captured DNA molecule is shown in FIG. 10.

After 20 sec, the FSM reversed the voltage to −20 mV, forcing the DNAtoward the cis side of the pore with enough force to abut the 5′ duplexagainst the trans-side end of the channel, and dangle the ss-ds junctionof the 3′ end hairpin into the cis chamber. The −20 mV voltage was foundto be small enough to not unzip the 5′-end primer duplex. The amount oftime at the −20 mV voltage is referred to as the fishing time t_(fish),measured in seconds. Application of −20 mV for tfish seconds is referredto as the fishing mode of the control logic.

After t_(fish)=5 seconds at −20 mV, the FSM changed the voltage to 180mV, then monitored (thresholded) the mean filtered amplitude to diagnosethe identity of the molecule in the pore as either DNA alone orenzyme-bound DNA. If unbound DNA was diagnosed ([15.75, 21.25] pAthreshold), voltage was revered to −20 mV to restart the fishing mode.Otherwise, the FSM continued to monitor the filtered amplitude. Within aKF/dGTP-bound event, upon diagnosis of the terminal step ([15.75, 21.25]pA threshold), voltage was reversed to −20 mV to restart the fishingmode.

Application of 180 mV until unbound DNA is diagnosed (by DNA alone or byreaching the terminal step of an enzyme-bound event) is referred to asthe probing mode of the control logic. The first nine fish-then-probeactions within a tethered DNA experiment are displayed in FIG. 11. Oncethe DNA is tethered, and the FSM logic begins the fish-then-probe cycle,only the unbound DNA threshold is used for diagnosis, of unbound DNA orof a terminal step within and enzyme-bound DNA event. The FSM logicrepeats the fishing mode then probing mode cycle until the tethered DNAmolecule translocates through the pore, and the open channel current isdetected. DNA translocates if the 3′-end hairpin is unzipped or if the5′-end duplex is unzipped. We expect that DNA translocation is mostlikely to occur by unzipping the 3′-end hairpin, since unzipping at 180mV can happen faster than DNA event diagnosis. The −20 mV voltage, onthe other hand, is less likely to unzip the 5′-end duplex, even forfishing times on the order of minutes. Post experiment analysis can beused to determine the frequency of DNA translocation in probing modeversus fishing mode. When the tethered DNA translocates and currentreturns to the open channel value, the FSM resets and monitors thecurrent for another event to tether a new DNA molecule.

In a second experiment a lower capture and probing voltage of 150 mV wasused, and a faster fishing time of t_(fish)=0.521 seconds was used.Based on experiments with DNA alone and DNA with KF and dGTP at constant150 mV, the unbound DNA threshold was set to [7.5, 15.5] pA and theKF/dGTP-bound DNA threshold was set to [19, 27] pA. Fishing and probingmodes are shown in FIG. 12, where probing reveals a DNA alone event.Fishing and probing modes are shown again in FIG. 13, where probingreveals an enzyme-bound DNA event. The FSM captured and tethered eightindependent DNA molecules. In total, 337 enzyme-bound DNA eventsoccurred in probing mode over a time period of 380 seconds. Analysis ofthe data shows the FSM/FPGA correctly diagnosed the terminal step inthese events 72% of the time. In the remaining 28%, fishing wasrestarted before a terminal step actually occurred in the enzyme-boundDNA event (referred to as a false positive). Offline analysis showedthat the EWMA filter resulted in zero false positives in this data.Online implementation of the EWMA filter in future tethered DNAexperiments will be used to gauge and improve the robustness of thefilter to false positives. An “unbound-DNA check” mechanism can beexplored to rule out/minimize false positives. The mechanism works asfollows: at the end of each probing mode, fish for a period too short toexpose the ss-ds junction in the cis-chamber, then re-probe to ensurethe DNA is unbound; if unbound, being fishing for period t_(fish); ifbound, wait until terminal step detected. Identification of the brieffishing period used to confirm that the DNA is unbound will be part ofour ongoing work.

Example XVIII Rapid Detection and Control to Probe Individual DNA andEnzyme-Bound DNA Molecules in a Nanopore

In the biological nanopore setup, a planar lipid bilayer is createdacross a 20 μm TELON aperture in a KCl solution. A single α-hemolysinprotein channel is inserted into the planar lipid. The channel (pore) is15 nm in length and varies in diameter. The cis-opening of the pore is2.6 nm wide, opening to a 3.6 nm vestibule before narrowing to alimiting 1.5 nm width at the beginning of the stem. The remainder of thestem up to the trans-opening is 2 nm wide. The vestibule is large enoughfor double-stranded DNA (dsDNA) to enter, but the limiting stem is justwide enough for ssDNA to pass through. Across the bilayer, AgClelectrodes are used to apply a potential that produces an ionic currentthrough the pore (FIG. 7). The field created by this voltage pulls thenegatively charged phosphate backbone of the ssDNA or RNA through thepore, passing from the cis side to the trans side of the pore with thetrans-side voltage positive. As molecules translocate, the pore becomespartially blocked by the translocating molecule, causing a momentarydrop in current. These translocation events can be characterized by theamplitude of the blockade current and the time the molecule spends inthe pore, defined as the dwell time. The DNA used in the experimentspresented here are comprised of ssDNA and dsDNA segments. Specifically,for the non-FPGA experiments disclosed herein, a 14 base pair hairpin(14 bphp) 67 nucleotides in total length was used. For the rest of theexperiments, a DNA oligomer that is 79 nucleotides total in length, witha 20 bphp was used. The hairpin was formed by folding the 3′ end overitself, creating 14 or 20 base pairs. The hairpin is thus thedouble-stranded segment, with the single-stranded segment 35 nucleotideslong for both the 14 and 20 bphp (4 unpaired bases in thedoubled-stranded end loop). Upon capture of the ssDNA end, the hairpinenters the pore vestibule and remains until the hairpin is unzipped. Aschematic of the nanopore system and an example 20 bphp translocationevent is illustrated in FIG. 8.

Correlations between the ionic current amplitude and features ofindividual DNA or RNA molecules translocating through the pore has beenshown through various assays using α-hemolysin nanopores. A near directcorrelation between the number of molecules passing through the pore andthe number of current drops has been demonstrated. Homopolymers of ssDNAand block copolymers of RNA are also distinguishable based on themeasurable differences in the blockade current amplitude or kinetics.However, translocation rates are too fast (up to 2 nucleotides/p sec)for sequencing individual nucleotides in heterogeneous single-strandedpolymers using existing biological nanopores. Here and in other studies,DNA with single and double stranded segments is used to increase thedwell time of nucleotides in the pore (0.5-5 msec, depending on appliedvoltage and dsDNA segment length). For example, blunt-ended hairpins,those with no single-stranded overhang, ranging from 3 to 9 bases longare used in Vercoutere et al (2001; Nat. Biotechnol, 19(3): 248-252, andVercoutere et al. (2003) Nucleic Acids Research, 31: 1311-1318), wheremachine learning methods were applied to the extended dwell time eventsto identify (sequence) the terminal base pair made up of the 3′ and 5′ends of the ssDNA.

Example XIX Voltage Control Using FSM/FPGA

The nanopore system is setup in a 0.3 mM KCl solution. A patch-clampamplifier, Molecular Devices AxoPatch 200B, regulates the appliedvoltage and measures the ionic current through the channel. The data arerecorded using the Molecular Devices Digidata 1440A digitizer, sampledat 50 kHz and low-pass filtered at 5 kHz with a four-pole Bessel filter.

The voltage control logic is programmed using a FSM within the LabVIEW 8software. The FSM logic is implemented on a field-programmable gatearray (FPGA) hardware system, National Instruments PCI-7831R. An FPGA isa reconfigurable hardware platform that permits fast measurement andvoltage reaction times (1 μsec output sample time). An FSM is a logicconstruct where program execution is broken up into a series ofindividual states. Each state has a command associated with it, andtransitions between states are a function of system measurements.Measurements of the pore current are processed and passed to the FSM asinputs. Changes in the FSM control logic are made as necessary, withoutthe need to re-compile and re-route the design to run on the FPGA. Thisachieves a balance between speed and flexibility, by enabling the systemto react to events on the order of a microsecond, while also allowingfor the control logic to be reconfigured as necessary betweenexperiments.

Example XX FSM Monitoring of Mean Filtered Current for DNA andEnzyme-Bound DNA Event Diagnosis

Blockade events, quantified by the blockage current and dwell time, canbe detected and monitored in real time using the FSM/FPGA. A mean filterapplied to the incoming current signal on the FPGA removes a largeportion of the peak-to-peak noise. Specifically, every 5.3 μsec, theFPGA samples the ionic current and computes a windowed mean amplitude.The FPGA tests if the mean is within a pre-specified range and thencontinues to test the mean every 0.2 msec after initial detection. Ifthe mean enters and remains within this range for four consecutivetests, the FSM logic diagnoses the blockade as a DNA hairpin event. Thetime delay between a DNA translocation event and diagnosis of a DNAtranslocation event is nominally 1.35 msec; 0.75 msec for the windowedmean to first enter the 17.2 to 22.8 pA range, and 0.6 msec for threemore confirmed tests, and 0.65 ms of computational delay. The meanfiltered current is used for DNA event diagnosis and triggers thetransitions between states in the FSM control logic.

The FSM control logic has been used to discern between DNA alone orDNA/enzyme complex using the nanopore system. Additionally, enzymedissociation from DNA can be detected and reacted to in real time usingthe FSM to detect the terminal steps present in the current signal. Theability to detect both DNA and DNA/enzyme complex in the pore can permitthe real-time identification of the base at the junction betweensingle-stranded and double-stranded DNA when KF is bound to a DNAhairpin and the correct nucleotide is present in the system, as detailedin this report.

Furthermore, the detection and control of single DNA hairpin moleculescan be expanded to include repeated capture of KF using a single copy ofDNA. One base can be identified when KF is pulled off a DNA hairpinusing a nanopore. Repeated capture and dissociation of KF from the samecopy of DNA can allow many bases to be sequenced provided a method forsingle-base ratcheting polymerase reaction is found. Current sequencingmethods are limited to read lengths of around one kilobase (1000 basepairs identified), but a nanopore-based sequencing method has potentialfor much longer read lengths when compared to traditional bulksequencing methods.

The bulk of the future work is dedicated to improving the detectionrobustness by increasing the signal-to-noise of the current signalthrough improved filtering and use of longer DNA hairpins. Also, adouble-checking scheme to ensure the enzyme has dissociated will beimplemented. Experiments that vary the concentration of KF and dNTP willalso be performed to find the detection limit of different complexes.

Example XXI Detection of Molecular Complexes

The interaction of DNA with Klenow fragment (KF) of Escherichia coli DNApolymerase I can be probed with the nanopore system. In the absence ofKF, capture and subsequent unzipping of 20 bphp at constant 180 mVreveals current blockades with 20 pA mean amplitude and 4 msec mediandwell time. Addition of KF and the dNTP complementary to the DNAtemplate base in the KF catalytic site yielded a substantial increase inblockade dwell times (110 msec median lifetime for dGTP), attributableto ternary (DNA/KF/dGTP) complexes. Closer investigation of suchblockades revealed a two-step pattern in greater than 97% of theblockades, the first step at 24 pA mean amplitude, and the second(terminal) step at 20 pA mean amplitude, lasting 4 ms consistent withthe hairpin kinetics alone. It was demonstrated that the transition fromstep one to two resulted in dissociation of KF from DNA first, followedby the hairpin dropping into the pore vestibule until unzippingoccurred. As an initial effort at voltage control of enzyme-bound DNA,efficient automated detection (<3 msec) of individual ternary complexeswas demonstrated, based on the characteristic 24 pA amplitude andtruncation of the blockade time by voltage reversal after 20 msec. The20 msec cutoff was used because 60% of events are longer than 20 msec inthe presence of the correct dNTP, while only 2% of events are longerthan 20 msec and in the detection range absent the correct dNTP, showingthat events longer than 20 msec usually correspond to ternary complexevents (FIG. 9). Detection was based on the mechanism described inSection 1.2.2 for calculating the windowed mean using the previous 1.5msec of signal and a detection range of 17.2 to 22.8 pA. The basis forchoosing this range is that ˜20 pA is the median amplitude for 14 and 20bphp events at 180 mV as well as the terminal step (FIG. 14).

The ability to diagnose individual events in real time shows potentialfor extending this system to sequencing. A single long dwell time event(>20 msec) gives high probability of a ternary complex event. Based onthe dNTP present in the system, the identity of the next base to beadded can be identified, achieving single base sequencing. For multiplebase reads, regulation of base polymerization is necessary to step alongthe addition of nucleotides. For every base added, enzyme-bound DNApresent in the pore can be probed for the presence of ternary complex,confirming the correct dNTP is present for polymerization. In theexperiments presented here, the dNTPs are di-deoxy terminated sopolymerization is stalled, preventing more than a single base additionto the hairpin. This use of di-deoxy terminators is the foundation ofmost sequencing methods employed today.

Example XXII Control of Individual DNA Molecules

Rapid detection (<2 msec) is based on computing a filtered meanamplitude, based on the last 0.75 msec of the ionic current, in realtime and monitoring the mean relative to an amplitude range consistentwith DNA hairpin blockades (20±2.8 pA). Upon detection, two methods ofvoltage control were demonstrated.

In the first method, dwell time extension is achieved by prompt voltagereduction, with the reduced voltage applied until the hairpin unzips. Ahigher voltage for capture increases the number of molecules examined,and the reduced voltage post-capture increases the dwell time to, inprinciple, facilitate sequencing. In particular, extending the life ofDNA hairpins in the pore increases the time within which a terminal baseidentification could be achieved using machine learning methods.

The second method reduces the voltage for a preset time (10 msec) andthen reverses the voltage to expel the molecule prior to hairpinunzipping. This demonstrates control authority to aggregate the dwelltimes of hundreds of blockade events. Additionally, it complementsprevious work, confirming the ability to detect both DNA-enzymeblockades and DNA hairpin blockades. Confirmation of the ability todiscern between each blockade type in real time is crucial to futurework. Ultimately, nanopore-based characterization of enzyme dynamicswill require direct detection and control of multiple DNA conformationsrelative to the enzyme, and direct control of enzyme-free DNA is aprerequisite toward developing this capability.

Direct control of ssDNA in a nanopore has been demonstrated, in whichdetection of DNA is based on monitoring the raw amplitude relative to athreshold level. Voltage level changes, comparable to those employedhere, were commanded to explore the zero and low voltage effects onssDNA-pore interactions. In contrast to thresholding the raw ioniccurrent amplitude, the windowed amplitude mean calculation used herefilters the current noise. Additionally, detection depends on the meanremaining within a preset amplitude range (<6 pA in spread) for multipleconsecutive comparisons, resulting in fewer false detections (falsepositives) than a single threshold comparison. This was an unexpectedlysuperior result.

Example XXIII Experiments and Results

A demonstration of direct FSM/FPGA control of single DNA molecules in ananopore is now described. In a first experiment, the objective was toefficiently detect DNA hairpin events, one molecule at a time andincrease the blockade dwell time by lowering the applied voltage from180 mV to 150 mV upon detection. This is referred to as “dwell timeextension control”. After completing this objective, the aggregation ofthe extended blockade dwell times was sought by expelling the DNA usingvoltage reversal of −50 mV after 10 msec at 150 mV. This is referred toas “dwell time aggregation control”. The motivation was to increase thenominal hairpin dwell time, but expel the molecule before unzipping thehairpin. A tighter distribution for the aggregated dwell time events, incontrast to the distribution of the extended dwell time events, willindicate that the objective has been met.

A typical 20 bphp event at constant 180 mV voltage is shown in FIGS. 8and 16 aI. The probability histogram of the base 10 logarithm of dwelltime (FIG. 16a III, solid bars) is unimodal, with median dwell time of2.8 msec. The median amplitude of the event plot in FIG. 16a II is 20.9pA with an interquartile range (IQR) of 1.7 pA. Only 6% of events are inthe subset range of 13 to 18 pA (FIG. 16a III, open bars). For the sameexperiment at constant 150 mV voltage (data not shown), the eventscluster around a median amplitude of 14.7 pA and 87% of 150 mV eventsare in the 13 to 18 pA range. Thus, under extension and aggregationcontrol for which the voltage is reduced to 150 mV for all detectedevents, a larger percentage of blockades should have a mean amplitudewithin the 13 to 18 pA range.

Example XXIV Dwell Time Extension Control (FIG. 16 b)

Upon diagnosis of a DNA hairpin event using the mean filtered current,the command voltage is reduced to 150 mV until the hairpin unzips andthe DNA translocates through the pore. Using 180 mV for capture resultsin more events than 150 mV, while reducing to 150 mV extends the life ofthe hairpin. Again, dwell time extension is useful for sequencing bymachine learning methods. The extended time can also be used to increasethe likelihood of correctly detecting DNA or DNA-enzyme configurations(states), by increasing the time during which the mean must residewithin the amplitude threshold corresponding to each state. After eachtranslocation, the FPGA resets the voltage to 180 mV. A representativeevent is shown in FIG. 16b I. The event plot (FIG. 16b II) pattern showsthat events faster than the nominal diagnosis time of ˜1.4 msec areunaffected by extension control, and events with longer dwell timesconverge to the ˜15 pA mean amplitude as expected. The concave trend isalso consistent with the mean amplitude computation for each event. Inparticular, for an event at 21 pA for 1.4 msec and at 15 pA for x msec,an approximate event mean amplitude Ī is

$\overset{\_}{I} = \frac{{1.4*21} + {15*x}}{1.4 + x}$When x≈24 msec, as in FIG. 16b I, Ī=15 pA. The fraction of events withinthe subset range 13 to 18 pA increased to 41% and is shown in the openbar histogram overlaid on the probability (filled bars) histogram (FIG.16b III).

Example XXV Dwell Time Aggregation Control (FIG. 16 c)

The objective was to aggregate the dwell times of the extended events byapplying 150 mV for 10 msec upon diagnosis of a hairpin event, followedby voltage reversal of −50 mV for 5 msec. The reversal time of 5 msec isknown to sufficiently clear the DNA from the channel, prepping the porefor the next event. The aggregation control would imply a measure ofcontrol over the distribution of the events, in addition to control ofthe individual molecular events. A representative event is shown in FIG.16c I. As before, the event plot (FIG. 16c II) pattern shows that eventsfaster than the nominal diagnosis time of ˜1.4 msec are unaffected byaggregation control. Using the previous equation, for an event at 21 pAfor 1.4 msec and at 15 pA for 10 msec, the approximate event meanamplitude is Ī=16 pA. Within the subset range of 13 to 18 pA, the medianis 16 pA with 0.7 pA IQR, precisely the approximate mean calculation.The fraction of events within the subset range 13 to 18 pA increased to55%, shown in the open bar histogram overlaid on the filled barprobability histogram (FIG. 16c III). For the subset of events, a mediandwell time of 12.4 msec is commensurate with a brief delay, required todiagnose hairpin state, plus 10 msec extension time. An IQR of 0.1 forthe open bar subset histogram indicates that the aggregation objectivehas been achieved. Regarding the impact of control on the distributionof events, 43% of all events in FIG. 16c II fall within the dwell timerange of 12-13 msec and the amplitude range of 13-18 pA.

Example XXVI Tethered DNA

Preliminary experiments were run with KF bound to a 20 base pair DNAhairpin (20 bphp). A single 20 bphp is threaded back and forth throughthe pore such that KF binds with the DNA multiple times. In thisexperiment, 1 μM 100mer ssDNA, 5 mM MgCl₂, 2 μM KF, and 200 μM of dGTPwere present in the cis well of the pore. The ssDNA oligomer wasdesigned such that a 20mer hairpin forms on the 3′ end. On the transside, there was 2 μM of a 20 base pair (20mer) primer complementary tothe sequence at the 5′ end of the DNA hairpin in the cis side.

With voltage applied, DNA was drawn through the pore with the 5′ endtranslocating first. When a 20 pA event characteristic of a ssDNAtranslocation event was detected, the FSM reduced the potential to 50mV, a level sufficient enough to hold the molecule in the pore but notstrong enough to shear the hairpin. If a 24 pA event characteristic ofenzyme-bound DNA was detected, application of voltage was continueduntil the enzyme dissociated, leaving the bare DNA in the pore, at whichpoint the voltage was reduced to 50 mV to hold the molecule in the pore.The molecule was held in the pore for 20 sec, a time found to besufficient for the 20mer primer to anneal to the 5′ end of the DNA at 2μM primer concentration. With both ends of the DNA consisting of 20merdouble-stranded segments, the molecule was restrained from immediatelytranslocating. After the primer annealing waiting time, the FSM reversedthe voltage to −20 mV, pulling the DNA toward the cis side of the porewith enough force to dangle it in solution but not to shear thetrans-side primer. The voltage stayed at −20 mV for 5 sec, after whichthe FSM changed the voltage to 180 mV to diagnose the identity of themolecule in the pore; either DNA alone, DNA/KF binary complex, orDNA/KF/dGTP ternary complex. If enzyme-bound, as presumed if ˜24 pA isobserved, the FSM monitored the current signal for the 20 pA terminalstep, the point when KF has dissociated but before the DNA translocates,to reverse the voltage back to −20 mV to attempt to capture another KF.If the FSM failed to detect the DNA molecule before it translocated, thecurrent returned to the open channel current of ˜60 pA, and the FSMwould monitor the current for another DNA translocation event and repeatthe fishing process (FIG. 17). If no enzyme is captured during aparticular fishing attempt, the FSM tried fishing again until enzymecapture did occur. For the data analyzed from this experiment, five DNAcopies were captured and used to fish for KF. Long dwell time events(that is, events >20 msec) were recorded for 95.1% of fishing attemptsthough no analysis has been done to determine the number of KFdissociation events that were correctly reacted to by the FSM.

After performing the initial proof-of-concept experiments, a second runof fishing experiments were run that yielded better results. Using afishing time of 0.521 seconds, the FSM captured eight copies of the sameDNA hairpin and reacted to 337 potential KF dissociation events over atime period of 380 seconds. Post analysis of the data shows the FPGAcorrectly detected and reacted to an enzyme dissociation event for71.86% of KF captures, for example, 74 of the 337 potential dissociationevents were false positives.

Example XXVII Mitigating False-Enzyme Dissociation Detection

In the data presented above, the dissociation of the enzyme is detectedby mean filtering the nanopore current signal and checking to see if itis within a chosen amplitude range. This method of smoothing yielded alarge number of false detections. As an improvement to this filteringscheme, an exponentially weighted moving average (EWMA) filter canreplace the mean filter that the FPGA used. The EWMA filter is a digitalimplementation of an analog RC filter, commonly used for signalsmoothing in electrical engineering applications. The filter calculatesa moving average that places exponentially less significance on pastsamples. EWMA filtering also performs signal smoothing more efficientlythan a simple moving average due to its recursive implementation.However, experimental testing still needs to be done to tune the filterfor nanopore current signal analysis.

To more robustly detect enzyme dissociation events, a KF dissociationcheck needs to be implemented to ensure fishing is being done with bareDNA. When the FPGA detects KF dissociation, it will fish for a period oftime sufficiently fast so KF will not bind and then it will check theDNA for the presence of enzyme. If only bare DNA is diagnosed (currentis ˜20 pA), then the enzyme has dissociated and the system can attemptto capture another enzyme. This check is important for performingexperiments to collect information on repeat events. For the data to bevalid and statistically accurate, each detected event must be a newenzyme binding event.

The majority of long dwell time events correspond to strong KF bindingevents, for example, the next dNTP to be added to the template strand ispresent in the nanopore system, when saturating levels of KF and thecorrect dNTP are present. Multiple long dwell time events in a rowimprove confidence in base identification because repeated sequentiallong dwell time events occur even less often when the correct dNTP to beadded is absent than when it is present. Here is where KF fishing willshow its utility. Separate work is being done to model the dwell timeevents as a Poisson process so a Phred quality score can be applied to abase identity diagnosis based on the number of repeated sequential longdwell time events. The Phred system is an accuracy metric used commonlyin DNA sequencing. For example, a 90% accurate call would be a Q₁₀ onthe Phred scale and a 99% accurate call would be Q₂₀. Q₂₀ is consideredthe standard level of quality in DNA sequencing at the time of writing.

Another method to improve the detectability of the current step at theend of enzyme events is to use a longer hairpin and run the experimentsat a higher voltage. The signal-tonoise of the channel current willimprove due to higher ion flow through the channel, making the terminalsteps more prominent.

Example XXVIII Voltage Titration Experiments

A more quantitative connection between the amplitude and duration of theterminal step and the applied voltage may be made. The goals here are toreveal the repeatability of the terminal step and show how its structureis consistent with DNA alone at different voltages. An in-depthcharacterization of the terminal step allows for better control of theterminal step. Constant voltage experiments are run at four differentvoltages with DNA alone as well as DNA/KF/dNTP ternary complex, usingsaturating levels of each substrate (1 μM, 2 μM, and 200 μMrespectively). Voltages are 220, 200, 180, and 160 mV. A 24 bphp is usedrather than the 20 bphp used in the other tethered experiments to extendthe dwell time at higher voltages. Higher voltages are run first todetermine a practical upper limit for an applied voltage that yieldsdetectable terminal step event durations (≧1 msec).

Example XXIX Terminal Step Control Experiments

As described above, it is necessary to show accurate detection andreaction to the terminal step. As stated earlier, 97% of enzyme-boundevents showed the terminal step, therefore, this is the theoreticalmaximum detection rate. Detection and reaction to the terminal step willbe shown by voltage reversal upon detection, aggregating the terminalstep duration. A high probing voltage, as used above, gives moreresolution between the bound and unbound current levels. Experiments arerun with DNA alone as well as DNA/KF/dNTP ternary complex, usingsaturating levels of each substrate. Robustness to false positives maybe shown by verifying accurate detection offline.

Example XXX Terminal Step Control Experiments: Tethered DNAConfiguration with Fishing Time Titration

A repeat of what was achieved above is performed but with tethered DNA.Titration of the fishing time is performed to reproduce the ratio of DNAalone events to ternary complex events comparable to those in thenon-tethered DNA experiments. This information helps set limits on thefishing time to maintain representative sampling of the contents of thecis well. Experiments are run with DNA alone as well as DNA/KF/dNTPternary complex; using saturating levels of each substrate.

Example XXXI Fishing Titration Experiments

Titration of KF and dGTP are performed. The percentage of long eventsare recorded as a function of KF and dGTP concentration. Experiments arerun at the same high capture voltage as above. The same concentrationintervals for KF and dGTP as in the supplement of Benner et al (2007)Sequence specific detection of DNA polymerase binding using ananopore-based state machine. Submitted to Nature Methods) are used:(KF=[0, 0.25, 0.5, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0] μM;dGTP=[0, 0, 0, 0, 0, 2.5, 7.5, 15, 30, 60, 120, 200] μM).

Example XXXII Other Enzyme Studies the FPGA/FSM Nanopore System can Alsobe Used for Other Enzyme Studies

Applying voltage ramps upon capture of DNA/enzyme complexes can producedata to calculate bond energy landscapes using voltage forcespectroscopy. Also, DNA's interaction with the pore can be characterizedusing feedback control of the applied voltage. Regulation of enzymecatalysis can be by achieved applying tension to DNA occupying the pore,counteracting the enzymes' processive force.

Example XXXIII Blocking Oligonucleotide (Oligomer) can Limit DNAPolymerase Activity at a Nanopore

A DNA primer/template duplex (about 1 μM) in a solution containing allfour dNTP (about 200 uM) substrates and Mg²⁺ (about 5 mM), and aprocessive DNA polymerase (about 1 uM) is placed in contact with asingle nanopore (for example, a-hemolysin). A voltage is applied suchthat negatively charged DNA is drawn into the pore. The primer/templateduplex is also annealed to a sequence specific molecule such as the onesshown in FIG. 19. These blocking molecules either inhibit binding of thepolymerase at the initiation site or they allow binding but hinderpolymerase-catalyzed strand synthesis. The blocking molecule is unzippedunder the effect of the applied voltage (FIG. 22) and synthesis canensue. In the case of blocking molecules 19(d) to 19(g) in FIG. 19, thedC tail at the 3″end favors the unzipping process in the pore. Theimportant point of this technology is that only the strand captured bythe nanopore is unlocked from the blocking oligomer at the instant it isto be examined.

FIG. 20 shows blocking oligomer inhibition of bulk phase primerextension (DNA synthesis) by T7 DNA polymerase (exo-). Methyleneblue-stained denaturing PAGE of reaction products following incubationfor 40 minutes in nanopore buffer at 23° C. with the components listedbelow for each lane:

lane reaction components 1 primer/template, T7DNAP, dNTPs 2primer/template, T7DNAP 3 primer/template 4 primer/template, dNTPs,T7DNAP, blocking oligomer e.ii 5 primer/template, blocking oligomer e.ii6 primer/template, dNTPs, T7DNAP, blocking oligomer e.i 7primer/template, dNTPs, blocking oligomer e.i 8 primer/template, dNTPs,T7DNAP, blocking oligomer d 9 primer/template, blocking oligomer d

Arrows below the gel highlight key findings: Lane 1 shows the loss ofthe primer band and concomitant appearance of extension products in thepresence of T7 DNA polymerase and dNTPs. The extension products do notappear if polymerase or dNTPs are omitted from the reaction (FIG. 20,lanes 2 and 3). Addition of blocking oligomer e.ii prevents full lengthprimer extension in the presence of enzyme and dNTPs (lane 4); a smallamount of single-nucleotide addition product is observed. Blockingoligomers d (lane 8) or e.i (lane 6) yield partial inhibition of primerextension.

Example XXXIV The Nanopore Device Reliably Reports Capture ofPolymerase-DNA-dNTP Complexes Formed in the Bulk Phase (FIG. 21)

The letters (a-d) above indicated features in the current trace (FIG.21) correspond to the letters in the cartoon scheme. (a) Absent DNA, theopen channel ionic current through the α-hemolysin nanopore is ˜53 pA at160 mV applied potential in 0.3M KCl. (b) The capture of apolymerase/DNA/dNTP complex causes the current to drop to acharacteristic enzyme-bound state level (I_(EBS)). This currentreduction occurs when the bound enzyme, which is too large to enter thepore vestibule, holds the duplex portion of the DNA substrate atop thepore, with the single-stranded template suspended in the pore lumen. (c)Upon voltage-promoted enzyme dissociation, the duplex DNA segment isdrawn into the pore vestibule, causing a further current decrease. WhenDNA that is not enzyme bound is captured, this lower current is the onlylevel that is detected. (d) The translocation of the DNA leaves the poreunoccupied and the current returns to the open channel amplitude. A 2-Dplot of dwell time vs amplitude of hundreds of similar events is alsoincluded.

Example XXXV Nanopore Evidence that Blocking Oligomers Prevent T7 DNAPolymerase Binding in Bulk Phase

FIG. 22 demonstrates how DNA primer/template is pre-annealed withblocking oligomer e.ii then added to the nanopore chamber in thepresence of T7 DNA pol (exo-) and the dGTP complement to the dC templatebase at n=0. The letters (a)-(e) above features in the current tracecorrespond to the letters in the cartoon scheme. (a) Open channelcurrent is observed when no molecule is in the pore. (b) Thepre-annealed blocking oligomer prevents the binding of the T7 DNAPol(exo-) to the DNA and just DNA can be captured in the pore, whichproduces a low amplitude current trace. (c) The blocking oligomer isunzipped against the pore and (d) the DNA template/primer duplex dropsinto the nanopore vestibule. (e) The translocation of the DNA leaves thepore unoccupied and the current returns to the open channel amplitude.

Example XXXVI Binding of T7 DNA pol to Individual DNA Substrates isActivated Electronically at the Nanopore

The utility of a given blocking oligomer is determined by testingwhether it is readily unzipped from the captured DNA template by thenanopore electric field, rendering individual molecules that wereblocked in bulk phase competent to bind enzyme after capture. Letters(a)-(e) in the current trace correspond to letters in the cartoon schemeshown in FIG. 23. (a) The DNA primer/template is pre-annealed with theblocking oligomer. Upon capture of the DNA template by the nanoporeelectric field, the polydC tail of the blocking oligomer is wedgedagainst the exterior of the αα-HL heptamer causing the oligomer to unzipas the DNA template is driven further into the pore. When the capturelevel is detected, the voltage is reduced and the DNA strand in thetrans compartment is allowed to anneal to a ssDNA reverse complement.This forms a duplex DNA dumbbell, non-covalently tethering the DNA inthe pore. At this membrane potential, the n=0 position of the DNAtemplate is protected from interacting with polymerase. (b)

The potential is reversed to drive the DNA primer/template up into thecis compartment where it can bind polymerase and dNTP substrates forminga ternary complex. The length of this ‘fishing’ period is determined bythe user, and can range from 0.5 ms up to an arbitrarily long period ofseveral seconds. (c) Following fishing, the membrane voltage is reversedagain, drawing the DNA template back toward the nanopore orifice. If anenzyme molecule is bound to the DNA during the ‘fishing’ time, an ioniccurrent characteristic of enzyme binding (I_(EBS)) is detected. (d) Uponvoltage-promoted enzyme dissociation, the duplex DNA segment is drawninto the pore vestibule, causing a further current decrease to a levelcharacteristic of unbound DNA. The FSM logic tests for this currentlevel. When unbound DNA is detected, the FSM executes a return to thenegative voltage fishing period for a new fishing cycle. (e) The processis repeated until the DNA translocates and open channel current isdetected. At this point the system returns to the initial state untilanother blocked DNA is captured.

The current trace and the accompanying 2-D plot of dwell time vs.amplitude for hundreds of similar events illustrate the key finding:under the same physico-chemical conditions as in the experimentillustrated in FIG. 22, FSM logic allows electronic activation of thesubstrate by unzipping of the blocking oligomer, and controlleddetection of enzyme binding to the individual DNA substrate tethered inthe nanopore.

Example XXXVII Polymerase-Catalyzed Nucleotide Addition Proceeds at theNanopore Following Unzipping of the Blocking Oligomer (FIG. 24)

FIG. 24(a) DNA primer/template bearing the 3′-OH terminus required forpolymerase-catalyzed primer extension is pre-annealed with blockingoligomer, and added to the nanopore chamber. (b) upon template capture,the blocking oligomer is unzipped and (c) a tethering oligomer isannealed to the DNA on the trans side of the nanopore. (d) When themembrane potential is reversed, the activated dsDNA/ssDNA junction atn=0 is exposed to T7 DNA polymerase and substrates in the ciscompartment. If the first round of catalysis does not occur during theprogrammed fishing interval, re-probing of the dsDNA/ssDNA junctionresults in ionic currents characteristic of DNA that is not enzymebound. In the current trace shown, there were ˜30 consecutive probingsteps of this class from 0 to 7 seconds. (e) With dideoxy-GTP (100 uM),and dATP (400 uM), present in the nanopore cis chamber, the followingsteps can occur, in this order: T7 DNA pol binding, catalysis of ddGTPincorporation opposite the templating dC nucleotide at n=0, and dATPbinding to form a stable ternary complex. If these steps occur duringthe fishing interval a ternary complex is drawn back atop the poreduring the probing step. This yields an event with a higher current(about 29 pA) and a significantly longer dwell time (steps (e), (f) inthe cartoon, and the black arrow at ˜7 seconds). Subsequent I_(EBS)values are observed at higher frequency (gray arrows) because thechemistry step was completed at 7 sec, and only ternary complexformation is required thereafter.

Example XXXVIII DNA Translocation Through the Nanopore in Real TimeDriven by T7 DNA Polymerase (FIG. 25)

FIG. 25 (a) shows the template (SEQ ID NO:1) used in 10 nt additionsynthesis experiment. The binding site for the 23 mer synthesis primeris underlined, the unique G residue at position+33 is in red, and theabasic insert is shown as blue Xs. Sequences at the 5″end of thetemplate, which include the binding site for the tethering oligomer onthe trans side of the nanopore, is not shown. (b) Current trace forfishing experiment in which T7DNAP catalyzes the addition of 10nucleotides up to a unique ternary complex endpoint. The fish and probeprotocol used for this experiment is detailed in FIGS. 18 & 19. The fishtime was 20 ms with a 90 mV probing step. (i) As synthesis begins fromthe 23 mer primer, standard DNA residues occupy the pore lumen,affording little discrimination between the enzyme bound state (EBS) andthe terminal current step when complexes are drawn back to the poreduring the probing step. (ii) As nucleotides are added during subsequentfishing intervals, the enzyme advances on the template, drawing theabasic insert closer to the pore lumen in single nt steps, thus higheramplitude EBS events emerge. A probing event with three discreteamplitude levels is shown, corresponding to the two EBS positions (9 pAand 11 pA) before the ternary endpoint (12 pA). Once this endpoint isreached, whether or not subsequent fishing events yield an EBS isdetermined by the probability of ternary complex assembly during thefishing interval. Thus the three-amplitude event was followed by aunbound DNA event (iii), followed after next fishing interval by a longternary complex event (iv) confirming that the 12 pA endpoint had beenreached.

Example XXXVIX Screening Molecules for Specific Binding with thePolynucleotide or Protein Conjugate

The polynucleotide, or fragments thereof, are labeled with ³²P-dCTP,Cy3-dCTP, or Cy5-dCTP (Amersham Pharmacia Biotech), or with BIODIPY orFITC (Molecular Probes, Eugene Oreg.), respectively. Similarly, theconjugate comprising a complex of polynucleotide and a binding proteinthereof can be labeled with radionucleide or fluorescent probes.Libraries of candidate molecules or compounds previously arranged on asubstrate are incubated in the presence of labeled polynucleotide orprotein. After incubation under conditions for either a polynucleotideor amino acid molecule, the substrate is washed, and any position on thesubstrate retaining label, which indicates specific binding or complexformation, is assayed, and the ligand is identified. Data obtained usingdifferent concentrations of the polynucleotide or protein are used tocalculate affinity between the labeled polynucleotide or protein and thebound molecule.

Example XXXX Screening Drug Candidates for Specific Binding with thePolynucleotide or Protein Conjugate

A drug candidate, such as a statin, is introduced into a chamber asdescribed herein, the chamber comprising a polynucleotide complex, ablocking oligomer, and a transcription factor having a binding affinityfor the statin of at least 10⁸ M. The transcription factor comprisesconserved domains that bind to a conserved element that is encoded by aportion of the polynucleotide complex. In vivo, for example in theliver, the statin binds to the transcription factor (TF) that activatesbinding of the transcription factor to the conserved element, therebyrecruiting RNA polymerase to the transcriptional activation site. Thesequence of the blocking oligomer is designed to prevent binding of theTF in the presence of a statin having a binding affinity of at least 10⁸M. When the polynucleotide complex/blocking oligomer is translocated toand thence partially through the nanopore, the blocking oligomer isstripped from the polynucleotide complex, thereby revealing the bindingsite of the polynucleotide complex for the activated TF. Candidatestatins are then screened to identify those with binding affinity forthe TF that correlates with the release of blocking oligomer and partialtranslocation of and subsequent catalysis of the polynucleotide complexthrough the nanopore.

Those skilled in the art will appreciate that various adaptations andmodifications of the just-described embodiments can be configuredwithout departing from the scope and spirit of the invention. Othersuitable techniques and methods known in the art can be applied innumerous specific modalities by one skilled in the art and in light ofthe description of the present invention described herein. Therefore, itis to be understood that the invention can be practiced other than asspecifically described herein. The above description is intended to beillustrative, and not restrictive. Many other embodiments will beapparent to those of skill in the art upon reviewing the abovedescription. The scope of the invention should, therefore, be determinedwith reference to the appended claims, along with the full scope ofequivalents to which such claims are entitled.

What is claimed is:
 1. A method for controlling movement of apolynucleotide using voltage control, the method resulting inidentifying a sequence of a polynucleotide, the method comprising thesteps of: a) providing two separate adjacent chambers comprising amedium, an interface between the two chambers, the interface comprisinga material having at least one channel therethrough and wherein onechamber is on the cis-side of the interface and the other chamber is onthe trans-side of the interface, the channel so dimensioned as to allowsequential monomer-by-monomer passage from the cis-side of the channelto the trans-side of the channel of only one polynucleotide strand at atime; b) providing an enzyme having binding activity for apolynucleotide, said enzyme being a polymerase; providing a blockingoligomer; providing a polynucleotide complex, wherein a portion of thepolynucleotide complex is double-stranded and a portion issingle-stranded; providing a complementary oligomer, wherein thecomplementary oligomer is complementary to a portion of the singlestranded polynucleotide; providing a substrate; c) introducing thepolynucleotide complex into one of the two chambers; introducing theblocking oligomer into the same chamber; allowing the blocking oligomerto bind to the polynucleotide complex; d) introducing the enzyme intothe same chamber; introducing the complementary oligomer into the otherchamber; e) applying a potential difference between the two chambers,thereby creating a first polarity, the first polarity causing the singlestranded portion of the polynucleotide to transpose through the channelto the trans-side thereby stripping the blocking oligomer from thepolynucleotide complex; f) measuring the electrical current through thechannel after removal of the blocking oligomer; g) providing a potentialdifference allowing the complementary oligomer to bind to thesingle-stranded polynucleotide; h) reversing the potential difference,thereby creating a reverse polarity; providing conditions to allow theenzyme to bind to the polynucleotide complex; providing conditions toallow the enzyme to incorporate substrate into the polynucleotide,thereby increasing length of the double-stranded portion; i) reversingthe potential difference a second time; j) measuring the electricalcurrent through the channel, thereby detecting a polynucleotide havingincorporated substrate or a polynucleotide bound to the enzyme; k)repeating any one of steps h) through j), thereby controlling movementof the polynucleotide in order to determine at least a portion of thesequence of the polynucleotide.
 2. The method of claim 1 furthercomprising comparing the electrical current value obtained at step f)with the current value obtained at step j).
 3. The method of claim 1further comprising comparing the electrical current value obtained atstep j) with the electrical current value obtained at a later time. 4.The method of claim 1 wherein the step of allowing the blocking oligomerto bind to the polynucleotide complex is performed prior to introducingthe polynucleotide complex and the blocking oligomer into the samechamber, and is followed by a step of introducing the polynucleotidecomplex and the blocking oligomer into the chamber.
 5. The method ofclaim 1 where there are a plurality of channels.
 6. The method of claim1 wherein the blocking oligomer is an oligonucleotide having partialcomplementarity to a portion of the polynucleotide complex.
 7. Themethod of claim 6 wherein the oligonucleotide having partialcomplementarity to a portion of the polynucleotide complex furthercomprises a duplex structure, formed with a portion of thepolynucleotide complex that is single-stranded, at one end of theoligonucleotide and a blocking moiety at the other end of theoligonucleotide.
 8. The method of claim 6 wherein the oligonucleotidehaving partial complementarity to a portion of the polynucleotidecomplex further comprises a hairpin loop structure at one end of theoligonucleotide.
 9. The method of claim 7 wherein the blocking moiety isselected from the group consisting of acridine, a peptide nucleic acid,a 2′-O-methyl group, a fluorescent compound, DAPI, an anthocyanin, greenfluorescent protein (GFP), β-glucuronidase, luciferase, Cy3, Cy5, aderivatized nucleotide, and a nucleotide isomer.
 10. The method of claim1 wherein the complementary oligomer is selected from the groupconsisting of an oligonucleotide complementary to the polynucleotide, apeptide nucleic acid, a locked nucleic acid, a derivatized nucleotide, anucleotide isomer and a DNA aptamer.
 11. The method of claim 1 whereinthe enzyme is selected from the group consisting of DNA polymerase, andRNA polymerase.
 12. The method of claim 1 further comprising the stepsof providing at least one reagent that initiates enzyme activity;introducing the reagent to the chamber comprising the polynucleotidecomplex; and incubating the chamber at a temperature sufficient tomaintain enzyme activity.
 13. The method of claim 12, wherein thereagent is a cofactor.
 14. The method of claim 13, wherein the cofactoris selected from the group consisting of Mg²⁺, Mn²⁺, Ca²⁺, ATP, NAD⁺,NADP⁺, and S-adenosylmethionine.
 15. The method of claim 1, wherein themedium is electrically conductive.
 16. The method of claim 1, whereinthe medium is an aqueous medium.
 17. The method of claim 1 wherein thesubstrate comprises a ribonucleotide selected from the group consistingof dATP, dGTP, TTP, dCTP, UTP, dUTP, ATP, GTP, TTP, CTP, and tRNA.